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ABSTRACT  
Brandy Lee Akin 
INVESTIGATING THE MOLECULAR MECHANISM OF PHOSPHOLAMBAN 
REGULATION OF THE Ca2+-PUMP OF CARDIAC SARCOPLASMIC 
RETICULUM 
 The Ca2+ pump or Ca2+-ATPase of cardiac sarcoplasmic reticulum, SERCA2a, 
is regulated by phospholamban (PLB), a small inhibitory phosphoprotein that 
decreases the apparent Ca2+ affinity of the enzyme.  We propose that PLB decreases 
Ca2+ affinity by stabilizing the Ca2+-free, E2·ATP state of the enzyme, thus blocking 
the transition to E1, the high Ca2+ affinity state required for Ca2+ binding and ATP 
hydrolysis.  The purpose of this dissertation research is to critically evaluate this idea 
using series of cross-linkable PLB mutants of increasing inhibitory strength (N30C-
PLB < PLB3 < PLB4).  Three hypotheses were tested; each specifically designed to 
address a fundamental point in the mechanism of PLB action. 
 Hypothesis 1:  SERCA2a with PLB bound is catalytically inactive.  The 
catalytic activity of SERCA2a irreversibly cross-linked to PLB (PLB/SER) was 
assessed.  Ca2+-ATPase activity, and formation of the phosphorylated intermediates 
were all completely inhibited.  Thus, PLB/SER is entirely catalytically inactive. 
 Hypothesis 2: PLB decreases the Ca2+ affinity of SERCA2a by competing with 
Ca2+ for binding to SERCA2a.  The functional effects of N30C-PLB, PLB3, and 
PLB4 on Ca2+-ATPase activity and phosphoenzyme formation were measured, and 
correlated with their binding interactions with SERCA2a measured by chemical 
cross-linking.  Successively higher Ca2+ concentrations were required to both activate 
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the enzyme co-expressed with N30C-PLB, PLB3, and PLB4 and to dissociate N30C-
PLB, PLB3, and PLB4 from SERCA2a, suggesting competition between PLB and 
Ca2+ for binding to SERCA2a.  This was confirmed with the Ca2+ pump mutant, 
D351A, which is catalytically inactive but retains strong Ca2+ binding.  Increasingly 
higher Ca2+ concentrations were also required to dissociate N30C-PLB, PLB3, and 
PLB4 from D351A, demonstrating directly that PLB competes with Ca2+ for binding 
to the Ca2+ pump. 
 Hypothesis 3: PLB binds exclusively to the Ca2+-free E2 state with bound 
nucleotide (E2·ATP).  Thapsigargin, vanadate, and nucleotide effects on PLB cross-
linking to SERCA2a were determined.  All three PLB mutants bound preferentially to 
E2 state with bound nucleotide (E2·ATP), and not at all to the thapsigargin or 
vanadate bound states.   
 We conclude that PLB inhibits SERCA2a activity by stabilizing a unique 
E2·ATP conformation that cannot bind Ca2+.   
 
 
      Larry R. Jones, M.D., Ph.D., Chair 
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CHAPTER 1—INTRODUCTION 
A.  EXCITATION-CONTRACTION COUPLING IN CARDIAC MYOCYTES 
 Ca2+ cycling through the SR of cardiac myocytes mediates contraction and 
relaxation of the heart (1).  A contraction event is initiated when an electrical stimulus 
(action potential) originating from pacemaker cells in the sinoatrial node, arrives at 
the T-tubule of the cardiomyocyte, depolarizing the plasma membrane (sarcolemma).  
Membrane depolarization activates the voltage-dependent L-type Ca2+ channel also 
known as the dihydropyridine receptor (Fig. 1).  Upon activation, the L-type Ca2+ 
channel permits small amount of extracellular “activator” Ca2+ to enter the cell.  
Then, through the process known as Ca2+ induced Ca2+ release, the “activator” Ca2+ 
triggers the opening of the Ca2+ release channels/ryanodine receptors in the 
membrane of the SR, and much of the intralumenal SR Ca2+ store is released into the 
cytoplasm (1).  As cytosolic Ca2+ concentration increases to micromolar levels, Ca2+ 
ions bind to the troponin C subunit of the regulatory troponin complex, initiating a 
conformational change that relieves inhibition of the actin/myosin cross-bridge cycle, 
allowing myofilament contraction to occur (1).  The mechanism by which the 
electrical signal (action potential) is converted into a mechanical response 
(myofilament contraction) is known as excitation-contraction coupling, a process 
fundamental to both cardiac and skeletal muscle.   
 Myofilament relaxation occurs when intracellular Ca2+ concentration is 
decreased to diastolic levels (nanomolar levels); Ca2+ is either removed from the cell 
by the plasma membrane Ca2+-ATPase and the Na+/Ca2+ exchanger, or pumped back 
into the lumen of the SR by the sarco(endo)plasmic reticulum Ca2+-ATPase, 
SERCA2a.  The majority of the intracellular Ca2+ (approximately 70%) is re-
sequestered back into the lumen of the SR by the Ca2+ pump, SERCA2a, making Ca2+ 
available for the next contraction (1).  Therefore, the rate of Ca2+ transport by 
SERCA2a determines both the rate of myofilament relaxation, and the size of the 
contractile-dependent SR Ca2+ store.  Ca2+ pump activity is regulated by 
phospholamban (PLB), a small inhibitory phosphoprotein that acts as a molecular 
brake on enzyme activity (2, 3).  Due to its essential role in maintaining Ca2+ 
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homeostasis in cardiac muscle cells, SERCA2a, and the mechanism by which 
SERCA2a activity is regulated by PLB is of great scientific and clinical interest.  The 
overall purpose of this dissertation research was to investigate the molecular 
mechanism of PLB regulation of SERCA2a. 
 
 
 
 
Figure 1.  Excitation-Contraction Coupling and Ca2+ Cycling in Cardiac Myocytes  Simplified 
scheme depicting E-C coupling and SR Ca2+ cycling in cardiac ventricular  myocytes.  Membrane 
depolarization causes Ca2+ to enter the cell through the voltage-dependent sarcolemmal Ca2+ 
channel.  This small influx in Ca2+ causes Ca2+ to be released from the SR by the ryanodine 
receptor (RYR), triggering myofilament contraction. Ca2+ is subsequently removed from the 
cytosol by the sarcolemmal Ca2+-ATPase, the Na+/Ca2+ exchanger, and by SERCA2a, the Ca2+-
ATPase in the SR membrane.  Most of the cytosolic Ca2+ is re-sequestered into the lumen of the SR 
by SERCA2a, allowing myofilament relaxation to occur and making Ca2+ available for the next 
contraction.  SERCA2a activity is modulated by the inhibitory phosphoprotein PLB.  De-
phosphorylated PLB inhibits Ca2+-ATPase activity, and PKA phosphorylation of PLB reverses this 
inhibition.  PKA activity is regulated via the β1-adrenergic receptor signaling pathway.  
Catecholamine activation of the β-receptor results in GS-mediated activation of adenylate cyclase 
(AC).  AC converts ATP to cAMP, and activates PKA.   
  3 
B.  REGULATION OF PLB BY THE β-ADRENERGIC SIGNALING 
PATHWAY 
 In response to physical or psychological stress, cardiac output (the volume of 
blood pumped per unit time) by human hearts is increased within seconds, and the 
percentage increase in cardiac output above that required under resting conditions is 
defined as the cardiac reserve (1-3).  The rate and strength of myocardial contraction 
and relaxation is regulated through the β-adrenergic signaling pathway (1-3).  When 
an individual becomes stressed, epinephrine is released into the blood stream by the 
sympathetic nervous system, activating β-adrenergic receptors in the plasma 
membrane of cardiac myocytes (Fig. 1).  The β-receptor is a G-protein coupled-
receptor, which when stimulated activates a hetero-trimeric G-protein complex.  The 
stimulatory Gsα subunit dissociates from the G-protein complex and activates 
adenylate cyclase.  Adenylate cyclase converts ATP to cAMP, increasing the 
concentration of cAMP in the cell, and activating cAMP-dependent protein kinase 
(PKA) (Fig. 1).  In response to β-adrenergic stimulation, PKA phosphorylates several 
downstream targets including the L-type Ca2+ channel, troponin I, and PLB (3).  PKA 
phosphorylation of the sarcolemmal Ca2+ channel permits a greater influx of 
extracellular Ca2+ across the plasma membrane (2).  PKA phosphorylation of troponin 
I, a subunit of the regulatory troponin complex, decreasing the affinity of troponin C 
for Ca2+, allowing for weaker myofilament contraction to occur at lower ionized Ca2+ 
concentrations (2).  Phosphorylation of PLB by PKA (or calmodulin kinase II 
(CaMKII), see below) reverses PLB inhibition of SERCA2a, increasing the apparent 
Ca2+ affinity of the enzyme and increasing the rate of Ca2+ uptake into the SR (2, 3).   
 However, although all three of these Ca2+ handling pathways contribute to the 
positive inotropic and lusitropic effects of β-adrenergic stimulation, studies have 
shown that the PLB/SERCA2a pathway is the dominant pathway responsible for 
PKA-mediated enhanced cardiac contractility (4, 5).  For example, PLB knock out 
mice (completely devoid of PLB expression) exhibited dramatically enhanced rates of 
contraction and relaxation, even under basal conditions, and were nearly completely 
unresponsive to β-adrenergic stimulation of the heart (4).  Thus contractility in the 
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hearts of mice lacking PLB is always near the maximal level, indicating that PKA 
phosphorylation of PLB is the central pathway responsible for β-adrenergic 
stimulation of the heart (4).  
 The effect of PKA phosphorylation of PLB on 45Ca2+-uptake by guinea pig 
ventricular SR vesicles is shown in Fig. 2 (5).  At 50 nM Ca2+ concentration, 
phosphorylation of PLB by PKA resulted in a two- to four-fold increase in SR Ca2+ 
up-take relative to control membranes.  Fig. 2 also shows the similar stimulatory 
effect of the anti-PLB 
monoclonal antibody, 2D12, on 
SR Ca2+up-take.  2D12 binds to 
residues 7-13 of PLB, near the 
site of PKA phosphorylation 
(Ser16), and reverses Ca2+ pump 
inhibition even more potently 
than PKA phosphorylation of 
PLB (5, 6).  It is important to 
note that the stimulatory effect 
of 2D12 on SR Ca2+-uptake  
was completely inhibited by 
addition of a PLB peptide 
(residues 2-25), which binds up 
the 2D12 antibody.  In the 
same study, the stimulatory 
effect of 2D12 (and blocking of 
the stimulatory effect of 2D12 
by the PLB peptide 2-25) was 
also demonstrated in intact 
cardiomyocytes, confirming 
that PKA phosphorylation of 
PLB is the main pathway responsible for β-adrenergic stimulated enhanced 
contractility (5).  It has been suggested by our group that PKA phosphorylation of 
 
 
Figure 2. Effect of the Catalytic Subunit of PKA (CSU) 
and the Anti-PLB Monoclonal Antibody (2D12) on 
Ca2+-Uptake by Guinea Pig Ventricular SR Vesicles 
Time courses of Ca2+-uptake are plotted for control 
vesicles (open circles), vesicles pre-phosphorylated with 
CSU (triangles), and vesicles pre-incubated with 2D12, 
with (filled circles) or without the PLB peptide 2-25 
(squares). Taken directly from Sham, J.S., Jones, L.R., and 
Morad, M. (1991) Am. J. Physiol. 261, H1344-H1349.  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PLB and binding of the 2D12 antibody to PLB both reverse Ca2+-pump inhibition by 
weakening protein-protein interactions between PLB and the Ca2+-ATPase (6).         
 In response to β-agonist stimulation, PLB is also phosphorylated by CaMKII 
at Thr17.  Like PKA phosphorylation, phosphorylation of PLB by CaMKII reverses 
PLB inhibition of SERCA2a, and it has been suggested that the effects of dual 
phosphorylation of PLB (at both Ser16 and Thr17) may be additive (2, 3).  However, 
the physiological role of CaMKII phosphorylation of PLB remains unclear (2, 6).  
Nevertheless, low basal contractility and heart rate are maintained in large part 
through PLB inhibition of Ca2+-ATPase activity, and cardiac output is increased 
through β-adrenergic stimulated phosphorylation of PLB by PKA and CaMKII (Fig. 
2 and 1-5). 
 
C.  THE β-ADRENERGIC PATHWAY AND HEART FAILURE 
 Although not the direct focus of this dissertation research, it seems important 
to briefly address the role of PLB in cardiac dysfunction and heart failure.  Heart 
failure is the condition in which the body’s oxygen requirements are not met due to 
insufficient pumping of blood by the heart.  It is a complex and progressive disorder 
with many causes that develops slowly over time.  Heart failure typically results from 
underlying conditions such as atherosclerosis or hypertension, which either damage 
the heart muscle directly, or make it harder for the heart to pump blood efficiently (7).  
In any case, an inefficient cardiovascular system means that the heart must work 
harder to circulate blood to the body, which leads to pathological growth and 
remodeling of the heart (7).  When left unchecked, this compensatory mechanism 
often leads to end-stage heart failure and sudden death.  On the molecular level, 
aberrant SR Ca2+-cyling is a characteristic of both cardiac dysfunction and end-stage 
heart failure (8).  Therefore, as a key regulatory complex controlling intracellular 
Ca2+ concentrations and contractility, the role of SERCA2a and PLB in pathological 
cardiac remodeling and heart failure is currently an active area of investigation (8).  
 Genetic analysis of individuals with family histories of heart failure led to the 
discovery of several mutated proteins that cause heritable cardiomyopathies (7). The 
  6 
preponderance has been found in contractile proteins, including mutations in actin, 
myosin, and tropomyosin (7).  More recently, however, mutated forms of PLB have 
been identified, which appear be directly responsible for causing the disease (9-11).  
In addition, in several recent studies of failing myocardium, reduced SERCA2a 
expression, altered PLB to SERCA2a ratio, or reduced phosphorylation of PLB was 
reported (12-14), suggesting that SERCA2a and PLB may be directly involved in the 
pathogenesis of heart failure.  On the contrary, Movsesian et al. reported that 
SERCA2a and PLB protein levels are unaltered in failing myocardium (15).  
Regardless, the pivotal role of the PLB/SERCA2a interaction in regulating 
intracellular Ca2+ concentrations and contractility has made them a potential target for 
therapeutic treatment of heart failure, underscoring the necessity of elucidating the 
molecular mechanism of PLB action. 
 
D.  THE MECHANISM OF Ca2+ TRANSPORT BY SERCA2a  
 SERCA is a large protein of nearly 1000 amino acids that actively transports 
Ca2+ into the lumen of the SR (and counter-transports luminal H+ to the cytoplasm) at 
the expense of ATP hydrolysis.  As a member of the P-type ATPase super-family, 
SERCA forms a high-energy phosphorylated intermediate as an integral part of its 
reaction cycle (16).  Formation of this high-energy intermediate drives Ca2+ transport 
across the SR membrane, during which the Ca2+-ATPase converts from a high Ca2+ 
affinity state (E1) to a low Ca2+ affinity state (E2) (17, 18).  Crystal structures of 
SERCA1a in both the E1 and E2 states have been determined and are shown in 
cartoon form in Fig. 3B and Fig. 3A, respectively (17, 18).  SERCA2a is the cardiac 
specific isoform of the Ca2+ pump, whereas SERCA1a is the isoform found in skeletal 
muscle (2, 3).  The two proteins have high sequence homology with greater than 90% 
identical amino acid residues (2, 3). 
 SERCA2a has a large transmembrane domain composed of 10 α-helices (M1-
M10), as well as a cytoplasmic head group with three functional domains: nucleotide 
binding (N) domain, phosphorylation (P) domain, and actuator (A) domain (Fig. 3).  
ATP binds within the N-domain, and the P-domain contains the conserved Asp351 that 
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is phosphorylated by ATP to form the high-energy acylphosphoprotein intermediate 
that drives Ca2+ transport across the membrane (17, 18).  Specific residues within the 
A-domain form a TGES loop, which is directly involved in hydrolysis of the 
phosphorylated intermediate (17, 18).  Two Ca2+ binding sites (I and II) are located 
side by side within the transmembrane domain between transmembrane helices M4, 
M5, and M6 (17, 18). 
 A simplified catalytic cycle of SERCA2a, beginning with the high Ca2+ 
affinity E1·ATP conformation is shown in Fig. 4.  Ca2+ binding at Site 1 
(E1·ATP·Ca1) is followed by a slow isomeric transition (E1·ATP·Ca1 to 
E1'·ATP·Ca1), which facilitates cooperative binding of the second Ca2+ ion at Site II 
(E1·ATP·Ca2).  Ca2+ occupancy at both sites triggers transfer of the gamma 
phosphate of the bound ATP to Asp351 within the P-domain, forming the high-energy  
 
 
 
Figure 3. Crystal Structures of the E2 and E1 Conformations of SERCA 3-D structures of 
SERCA1a in the E2 (a) and E1 (b) conformations with bound Thapsigargan and Ca2+ respectively. 
Image taken directly from Green, N.M and MacLennan (2002) Nature. 418, 598-599 (19).  
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acylphosphoprotein intermediate, E1~P·ADP·Ca2.  Next, as the Ca2+ pump converts 
from E1~P·ADP·Ca2 to E2-P·ADP·Ca2, Ca2+ is transported across the membrane and 
released into the SR lumen.  ADP dissociates (forming E2-P), followed by hydrolytic 
cleavage of the phosphorylated Asp351, producing inorganic phosphate bound, E2·Pi.  
Dissociation of Pi, and subsequent binding of ATP yields E2·ATP.  It should be noted 
that when the enzyme is in the Ca2+-free E2 state, the carboxyl groups involved in 
formation of the Ca2+ binding sites are all thought to be protonated, whereas when the 
enzyme is in the E1 state, the carboxyl groups are not protonated and have a high 
affinity for Ca2+ (18).  The high affinity Ca2+ pump inhibitor thapsigargin (TG) 
 
 
Figure 4. Reaction Cycle of SERCA2a E1 and E2 represent the high and low Ca2+-affinity 
conformations of SERCA2a, respectively.  After sequential binding of two Ca2+ ions to E1, the 
enzyme is phosphorylated with the γ-phosphate of ATP at Asp351, forming the high energy 
intermediate, E1~P.  Ca2+ translocation across the SR membrane occurs during the E1 to E2 
transition.  TG inhibits Ca2+-ATPase activity by forming a dead-end complex with the enzyme in 
E2 (E2·TG) (34). E2·TG has a greatly reduced affinity for ATP relative to TG-free E2 (61, 62).  
PLB cross-linking studies indicate that PLB binds preferentially to E2 with bound ATP 
(E2·ATP·PLB).  PLB does not bind to E2·TG or E2·cyclopiazonic acid (21), E2-P (22) or to the 
Ca2+ pump with Ca2+ binding site 1 (23) or both sites (22, 27) occupied. It is notable that under 
conditions favoring formation of E2 (the absence of Ca2+ and presence of DMSO) the Ca2+ pump 
can be phosphorylated in the reverse direction by Pi forming E2-P.  From Akin, B.L., Chen, Z., and 
Jones, L.R. (2010) J. Biol. Chem. 285, 28540-28552.   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inhibits Ca2+-ATPase activity by forming a dead-end complex with the enzyme in E2 
(E2·TG), and it was recently suggested that the E2 state stabilized by TG is the fully 
protonated HnE2 state (20 and Fig. 4).  Cross-linking studies by our group have 
suggested that PLB inhibits Ca2+ pump turnover by stabilizing the Ca2+-free, E2 state 
with bound nucleotide, E2·ATP (6, 21-23 and Fig. 4, and as further characterized by 
this dissertation research). 
 In addition to its role in catalysis, ATP also interacts with the enzyme in a 
non-catalytic, modulatory fashion, accelerating multiple steps in the Ca2+ pump 
reaction cycle, including the E2-P to E1·ATP·Ca2 transition (20).  In a recent study by 
Jensen et al. it was suggested that TG binds to the fully protonated HnE2 state of 
SERCA2a, and that ATP binding at the 
modulatory site (ATP binding site in E2) 
accelerates the E2-P to E1·ATP·Ca2 transition 
by stimulating deprotonation of E2,  initiating 
the E2 to E1 transition (20).  According to the 
authors, there is a single ATP binding site that 
converts from modulatory mode (E2·ATP) to 
catalytic mode (E1·ATP·Ca2).  In recently 
published work presented as part of this 
dissertation research, our group proposed that 
the conformation of SERCA2a that binds PLB 
is the deprotonated E2·ATP state with 
nucleotide bound at the modulatory site (24). 
 
E.  PLB STRUCTURE AND FUNCTION  
 PLB is a 52 amino acid single-span 
membrane protein localized to the SR of 
cardiac and smooth muscle cells (2, 3).  
Monomeric PLB has two structural domains: a 
cytosolic N-terminal domain I (residues 1-32), and a C-terminal transmembrane 
 
Figure 5. Amino Acid Sequence of 
PLB Amino acid sequence of canine 
PLB. Domains I (A and B) and II are 
shown. Transmembrane residues are 
shown in yellow.  Ser16 and Thr17 (blue) 
are the sites of phosphorylation. The 
residues involved in formation of the 
Leu/Iso zipper are shown in orange.  
Residues 7-13 comprise the epitope for 
the anti-PLB antibody, 2D12, which 
reverses PLB inhibtion of the Ca2+-
APTase.   
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domain II (residues 33-52) (Fig. 5).  Early analysis of PLB by SDS-PAGE showed 
that PLB monomers oligomerize to form stable homo-pentamers (2, 3).  Subsequent 
mutational analysis showed that the PLB pentamer is stabilized by an intra-molecular 
Leu/Ile zipper, formed by residues leu37, leu44, leu51, Ile40, and Ile47 within 
transmembrane domain II (25), and mutation of any of the residues to Ala destabilizes 
PLB pentamer formation and enhances Ca2+ pump inhibition by PLB (26, 27).  Based 
upon these results it was concluded the PLB monomer is the active species that binds 
to and inhibits Ca2+ pump activity, and that PLB inhibitory function is increased by 
mutations that increase PLB monomer content in the membrane (26, 27).  Due to their 
ability to decrease the Ca2+ affinity of SERCA2a (increase the KCa of enzyme 
activation) more than wild-type PLB, these superinhibitory monomeric PLB mutants 
were termed “supershifters” (26).  Subsequent mutagenesis studies showed that Ca2+ 
pump inhibition by PLB was also enhanced by mutations that did not affect the PLB 
monomer to pentamer ratio observed by SDS-PAGE (22, 28).  It was proposed that 
theses superinhibitory PLB mutants retaining the ability to form pentamers must have 
an increased binding affinity for the Ca2+ pump relative to wild-type PLB (22, 28).  
Collectively, all of these results suggested that there is dynamic equilibrium between 
PLB pentamers, PLB monomers, and PLB/SERCA2a heterodimers in the membrane, 
and PLB inhibition of Ca2+-ATPase activity is enhanced by point mutations that 
either increase PLB monomer formation by destabilizing the PLB pentamer (e.g. 
L37A (26, 27)), or otherwise enhance PLB monomer binding interactions with the 
Ca2+ pump (e.g. N27A (28) and V49G (22)).   
 Consistent with these in vitro studies, depressed cardiac function and super-
inhibition of the Ca2+-ATPase was observed transgenic mice overexpressing 
monomeric PLB supershifters (L37A (29)) and PLB supershifters retaining the ability 
to form pentamers (N27A (30) and V49G (31)), relative to mice overexpressing wild-
type PLB.  Mice overexpressing the pentameric PLB supershifters developed cardiac 
hypertrophy, dilated cardiomyopathy and premature death compared to mice 
overexpressing wild-type PLB (30, 31).  Moreover, whereas isoproterenol stimulation 
(activating the β1-adernergic pathway) completely reversed Ca2+-ATPase inhibition 
by the monomeric PLB supershifters, isoproterenol stimulation was not sufficient to 
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completely reverse the inhibitory effects of the more potent pentameric PLB 
supershifters (30-31).  These findings are consistent with the theory that PLB 
supershifters retaining the ability to form pentamers have a higher binding affinity for 
the Ca2+ pump relative to wild-type PLB.     
 
F.  DEVELOPING A MODEL OF PLB REGULATION OF SERCA2a USING 
CHEMICAL CROSS-LINKING 
 The work discussed thus far clearly demonstrates that PLB is a key regulator 
of myocardial contractile kinetics, and that proper regulation of Ca2+-ATPase activity 
by PLB is required for normal cardiac function and survival.  Yet despite its 
prominent role in regulating cardiac function, the physical basis of enzyme inhibition 
by PLB has remained unclear, and presently several fundamentally different models 
exist.   
 A major impediment 
to solving the molecular 
mechanism of PLB regulation 
of SERCA2a has been an 
inability to measure PLB 
binding interactions with the 
Ca2+ pump. Our group has        
overcome  this hurdle 
using chemical cross-linking.  
PLB can be irreversibly 
covalently coupled to 
SERCA2a in native 
membranes, facilitating direct 
measurement of PLB binding 
to SERCA2a.  This technique 
has enabled us to study 
protein-protein interactions 
 
 
 
Figure 6.  Structural Model for the Interaction Between 
PLB and SERCA2a A, Two independent structures for PLB 
were docked next to the structure of the E2 state of SERCA 
bound to TG.  The cyan PLB was derived from a monomeric 
mutant, whereas the yellow PLB was extracted from the 
pentameric structure of a construct corresponding to the WT 
human sequence.  B, Close-up of the C-terminus of PLB.  It 
is wedged between the lumenal end of M2 and a loop 
between M9 and M10 of SERCA (colored blue), suggesting 
that M2 must move to accommodate PLB binding and that 
Val49 controls access to this binding site. Taken directly from 
Chen, Z., Akin, B.L., Stokes, D.L., and Jones, L.R. (2006) 
J.Biol.Chem. 281, 14163-14172.  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between PLB and SERCA2a, and the allosteric factors that controlling the interaction 
(6, 21-24).  Using chemical cross-linking we have identified several key points of 
interaction between PLB and the Ca2+ pump, which in conjunction with the crystal 
structures of the enzyme (17, 18) enabled us to model the three-dimensional 
interactions between the two proteins (Fig. 6).  
 In initial cross-linking studies, fully functional, Cys-less PLB (with Cys 
residues 36, 41, and 46 mutated to Ala) was used as a background for making Cys 
scanning point mutants of PLB.  Lone Cys residues inserted at discrete locations 
within PLB were then probed for cross-linking to Cys or Lys residues of SERCA2a 
using homo (thiol specific), or heterobifunctional (thiol to amine specific) cross-
linking reagents, respectively.  Cys residues within both domain I (cytoplasmic) and 
domain II (transmembrane) of PLB have been cross-linked to Cys and Lys residues of 
SERCA2a at the cytoplasmic extension of M4 and at the C-terminus of M2 (Fig. 7).   
 
 
Figure 7.  Sites of PLB Cross-linking to SERCA2a with Homo- and Hetero-bifunctional 
Cross-linkers PLB mutants have been cross-linked to SERCA2a cytoplasmic extension of M4 
(red) and at the C-terminus of M2 (green).  Modified from Jones, L.R., Cornea, R.L., and Chen, Z. 
(2002) J. Biol. Chem. 277, 28319-28329.  
 
. 
  13 
 
 PLB cross-linking to SERCA2a at each of these sites was completely 
inhibited by micromolar Ca2+ concentration (Fig. 8).  This suggests that   binding   of 
PLB and Ca2+ to SERCA2a is mutually exclusive.  Importantly, when Ca2+ inhibition 
of PLB cross-linking was correlated with Ca2+ stimulation of Ca2+-ATPase activity, 
cross-linking was inhibited over the same range of Ca2+ concentration as Ca2+-
ATPase activity was stimulated.  This is exemplified in Fig. 9, which shows the 
cross-linking curve of N30C-PLB to Cys318 of WT-SERCA2a, correlated with the 
ATPase activity measured from the same microsomal prep.  Note that as micromolar 
Ca2+ increases, PLB cross-linking to SERCA2a is inhibited (panel A), whereas the 
Ca2+-ATPase is activated (panel B).  An inverse relationship between PLB cross-
linking to SERCA2a and Ca2+ pump inhibition has proven consistent with all cross-
 
 
 
Figure 8.  Ca2+ Inhibition of Cross-linking of Residues 45-52 of PLB to V89C-SERCA2a  I45C- 
through V49C-PLB and L51C- and L52C-PLB were cross-linked to V89C-SERCA2a with bBBr.  
M50C-PLB was cross-linked to V89C-SERCA2a with BMH. Cross-linking was conducted in buffer 
containing 1 mM EGTA with no added Ca2+ (EGTA), or in E2 buffer containing 10 µM added Ca2+, 
with no EGTA. Taken directly from Chen, Z., Akin, B.L., Stokes, D.L., and Jones, L.R. (2006) 
J.Biol.Chem. 281, 14163-1417.  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linking pairs discovered to 
date, strongly suggesting that 
PLB competes with Ca2+ for 
binding to the enzyme.  
Consistent with this 
interpretation, assays 
measuring Ca2+ inhibition of 
PLB cross-linking indicate that 
when PLB is phosphorylated 
by PKA, a lower concentration 
of Ca2+ is required to dissociate 
PLB from Ca2+ pump (Fig. 10).  
This suggests that 
phosphorylation of PLB at 
Ser16 by PKA decreases its binding affinity for the Ca2+ pump.   
  
 
 
 
Figure 10.  Ca2+ Effect on Cross-linking of Phosphorylated and Dephosphorylated PLB to 
SERCA2a  PLB pre-phosphorylated in the presence  (PKA) or absence (Con) of PKA was cross-linked 
to SERCA2a at varying Ca2+ concentrations. The inset shows the immunoblot with anti-PLB antibody 
obtained after cross-linking. Plot depicts cross-linking inhibition as a function of ionized Ca2+ 
concentration. Taken directly Chen, Z., Akin, B.L., and Jones, L.R. (2007) J. Biol. Chem. 282, 20968-
20976.   
 
Figure 9.  Effect of Ca2+on Cross-linking of N30C-PLB 
to SERCA2a with BMH  A, Ca2+ inhibition of PLB 
N30C-PLB cross-linking with BMH.  B, Ca2+-ATPase 
activity of the same microsomal preparation measured in 
the presence and absence of the anti-PLB antibody, 2D12, 
which reverses PLB inhibition like phosphorylation by 
protein kinase A. Taken from Jones, L.R., Cornea, R.L., 
and Chen, Z. (2002) J. Biol. Chem. 277, 28319-28329.   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 In addition to being completely 
inhibited by micromolar Ca2+ 
concentration (Figs. 8-10), another 
hallmark of the PLB to SERCA2a 
cross-linking reaction is its nucleotide 
dependence.  ATP stimulated PLB 
cross-linking to SERCA2a by 2-3-fold 
at nearly all cross-linking sites tested 
when measured in the absence of Ca2+ 
(Fig. 11).  This suggests that PLB 
binds preferentially to nucleotide-
bound E2 state (E2·ATP). PLB cross-
linking to SERCA2a was also 
stimulated by ADP, but was unaffected 
by AMP, measured in the absence of 
Ca2+ (21). This indicates that the β-
phosphate of the nucleotide is involved 
in formation of the E2 state that binds 
PLB.  
 Early kinetic studies showed 
that the E2 state of SERCA2a could be 
phosphorylated in the reverse direction 
by Pi to form E2-P (E2 + Pi  E2-P, 
or “back-door phosphorylation”) (32, 33). It was also shown that there are two 
distinct E2 conformations of SERCA2a: one with bound ATP (E2·ATP) which 
cannot be phosphorylated by Pi, and a second stabilized by low pH or Me2SO that is 
readily phosphorylated by Pi to form E2·Pi (32, 33). When PLB cross-linking to 
SERCA2a was measured simultaneously with E2-P formation by Pi, ATP stimulated 
PLB cross-linking to SERCA2a over the same concentration range as ATP inhibited 
formation of E2-P (Fig. 12).  Based upon these results it was concluded that PLB 
binds to E2·ATP, but not to E2-P or E2·Pi (22). 
 
 
 
Figure 11.  ATP Dependence of PLB Cross-
Linking  I45C- through L52C-PLC were co-
expressed with V89C-SERCA2a in Sf21 insect 
cells.  PLB was then cross-linked to V89C-
SERCA2a in the presence and absence of 3 mM 
ATP. Taken directly from Chen, Z., Akin, B.L., 
Stokes, D.L., and Jones, L.R. (2006) J.Biol.Chem. 
281, 14163-14172.  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 A final signature characteristic of the PLB to SERCA2a cross-linking reaction 
is its sensitivity to the Ca2+ pump inhibitor TG.  TG binds with nanomolar affinity to 
the Ca2+-ATPase in E2, forming a dead-end complex, E2·TG, and irreversibly 
inhibiting the enzyme (34, 35 and Fig. 2).  Measured in the absence of Ca2+, TG 
 
 
 
Figure 12.  ATP Concentration-Dependence on Cross-linking and E2-P Formation  N30C-
PLB co-expressed with WT-SERCA2a (A) and V49C-PLB co-expressed with V89C-SERCA2a 
(B) was cross-linked in E2-P buffer. Upper autoradiograms show E2-P formation, and middle 
autoradiograms show PLB cross-linked to SERCA2a.  The bottom graph shows the ATP 
concentration-dependence for stimulation of PLB-cross-linking to SERCA2a (open symbols) and 
for inhibition of E2-P formation (filled symbols).  In the plot, baseline values obtained in the 
absence of ATP were set at 0% and 100% for protein cross-linking and E2-P formation, 
respectively (n = 5). Taken directly from Chen, Z., Akin, B.L., Stokes, D.L., and Jones, L.R. 
(2006) J.Biol.Chem. 281, 14163-14172.  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completely inhibits PLB cross-linking to SERCA2a (Fig. 13A and B).  This indicates 
that PLB does not bind to the E2 state of SERCA2a stabilized by TG.  When ATP 
was included in assays measuring TG effects on PLB cross-linking, the Ki for TG 
inhibition of PLB cross-linking was increased by approximately 4-fold (Fig. 13C), 
strongly supporting the idea that PLB binds preferentially with the nucleotide bound 
Ca2+-ATPase in E2. 
 Collectively, these cross-linking results point to a simple mechanism of PLB 
regulation of SERCA2a shown in Fig. 14.  PLB stabilizes a single unique 
conformation of the Ca2+ pump, the low Ca2+ affinity E2·ATP state and blocks the 
transition to E1, the conformation required for high-affinity Ca2+ binding and ATP 
hydrolysis.  SERCA2a with PLB bound cannot bind Ca2+ and is catalytically inactive, 
and PLB must completely dissociate before the enzyme can transition to E1 and 
initiate Ca2+ transport.  By antagonizing formation of E1, PLB significantly decreases 
the fraction of Ca2+ pumps available to transport Ca2+ at sub-saturating Ca2+ 
 
 
 
Figure 13.  TG Inhibition of Cross-Linking of Residues 45-52 of PLB to V89C-SERCA2a  A, 
Cross-linking of PLB mutants to V89C-SERCA2a in the presence and absence of 40 µM TG.  B, 
TG inhibition of PLB cross-linking.  Upper panel shows immunoblots and Lower panel show the 
plot of TG inhibition of PLB cross-linking.  C, Effect of 3 mM ATP on TG inhibition of cross-
linking. Upper panels show immunoblots and Lower panel shows the graph of TG inhibition of 
cross-linking. From Chen, Z., Akin, B.L., Stokes, D.L., and Jones, L.R. (2006) J.Biol.Chem. 281, 
14163-14172.  
  18 
concentration.  This is manifested as a decrease in the apparent Ca2+ affinity of the 
Ca2+-ATPase, the hallmark of PLB inhibition (2, 3).  At saturating Ca2+ concentration 
PLB is not bound to the enzyme, therefore, PLB has no effect on maximal Ca2+-
ATPase activity.  Phosphorylation of PLB by PKA and binding of the 2D12 antibody 
to PLB decrease the affinity of SERCA2a for PLB, allowing PLB inhibition of Ca2+-
ATPase activity to be reversed at a lower Ca2+ concentration.      
   
 
 
Figure 14.  Our Model of PLB Regulation of SERCA2a Activity  There is a dynamic 
equilibrium between PLB pentamers, PLB monomers, and PLB/SERCA2a heterodimers. PLB 
binds exclusively to the E2·ATP conformation of the Ca2+ pump and immobilizes it in this state. 
Ca2+-ATPase inhibition by PLB is reversed by complete dissociation of PLB from SERCA2a, 
induced by micromolar Ca2+ concentration or by PLB phosphorylation and low micromolar Ca2+ 
concentration.   
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 This model of mutually exclusive binding of PLB and Ca2+ is consistent with 
the crystal structures of SERCA2a determined in both the E1 and E2 states (17, 18).  
Cross-linking studies predict that PLB binds to E2 of SERCA2a within a groove 
formed between transmembrane helices M2, M4, and M9 (Fig. 6).  When SERCA2a 
is in E1 with bound Ca2+, this groove is closed at the C-terminus (17, 18), blocking 
PLB access to the binding pocket.    
 However, despite strong biochemical and structural evidence supporting this 
model of PLB regulation of SERCA2a, several alternate models of PLB inhibition 
have recently emerged.  These models differ from the model just described in three 
main respects:  
 
 1) We maintain that PLB binding interactions with SERCA2a are dynamic, 
and PLB associates and dissociates from the enzyme in a Ca2+-dependent fashion.  On 
the other hand, other groups maintain that PLB is essentially a subunit of SERCA2a 
that remains tightly bound to the enzyme throughout the catalytic cycle (36, 37).  
 
 2) According to our model, PLB binds exclusively to the E2·ATP 
conformation of the Ca2+ pump and blocks the E2 to E1 transition.  However, others 
have suggested that PLB acts elsewhere, or at multiple points in the catalytic cycle to 
slow or inhibit enzyme turnover (36-41).  
 
 3) Our model states that high Ca2+ concentration completely dissociates PLB 
from the Ca2+ pump.  Therefore, at saturating Ca2+ concentration, PLB is not bound, 
and has no effect on maximal Ca2+-ATPase activity.  On the contrary, several recent 
studies have reported that PLB either decreased or increased the Vmax of the Ca2+-
ATPase at saturating Ca2+ concentration (42-45).     
 
G.  PURPOSE 
 The purpose of this dissertation research was to critically evaluate our model 
of PLB regulation of SERCA2a, and to clarify the major points of discrepancy 
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between our model and the other current models.  To do this I proposed three 
hypotheses to be tested, each one specifically designed to address a fundamental point 
in the mechanism of PLB action.    
  
 1.  HYPOTHESIS 1: SERCA2a WITH PLB BOUND IS 
 CATALYTICALLY INACTIVE 
 There are two schools of thought with respect to PLB binding interactions 
with SERCA2a.   In the first, PLB is essentially a subunit of SERCA2a that remains 
tightly bound to the enzyme throughout its entire reaction cycle.  Using fluorescent 
probes to monitor interactions between PLB and SERCA in both reconstituted and 
native membranes, Li et al. (36) and Chen et al. (37) concluded that PLB binds so 
tightly to SERCA2a that it essentially never dissociates, remaining bound to the 
enzyme throughout the full catalytic cycle.  On the other hand, several groups, 
including ours, have shown that there is a dynamic equilibrium between PLB 
pentamers, PLB monomers, and PLB-SERCA heterodimers (21, 46-50).  Moreover, 
based upon our recent work with chemical cross-linking we have proposed that PLB 
stabilizes the Ca2+ free, E2·ATP conformation of SERCA2a and blocks the E2 to E1 
transition.  In order for enzyme to transition to E1 and initiate Ca2+ transport, PLB 
must first completely dissociate from the enzyme (6, 21-23).  Thus, at any given time 
within a cardiomyocyte, there are two distinct populations of SERCA2a: one inactive 
population of SERCA2a with bound PLB (SERCA2a·PLB), and a second active, 
PLB-free population, pumping Ca2+ at the normal rate.  
 
a.  TESTING THE CATATLYTIC ACITIVITY OF SERCA2a 
WITH PLB BOUND 
 To address this point of uncertainty, I developed a method to test the catalytic 
activity of SERCA2a with PLB irreversibly bound to it.  First, chemical cross-linkers 
were used to covalently couple PLB to SERCA2a to form PLB/SER (PLB/SER refers 
to PLB covalently cross-linked to SERCA2a), and Ca2+-ATPase activity was 
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measured. Then, [γ-32P]ATP and 32Pi were used to phosphorylate PLB/SER, in order 
to determine if SERCA2a can undergo the catalytic half-reactions to form E1~P and 
E2-P, respectively, when PLB is bound.  Finally, PLB-free SERCA2a was resolved 
from PLB/SER via a cross-linking induced mobility-shift on LDS-PAGE, while 
maintaining the labile acyl-phosphate of E1~P and E2-P.  These experiments revealed 
that PLB/SER was entirely catalytically inactive and unphosphorylatable by either [γ-
32P]ATP or 32Pi, and thus forcibly kinetically stalled by the binding of PLB.  
 
 2.  HYPOTHESIS 2: PLB DECREASES THE Ca2+ AFFINITY OF 
 SERCA2a BY COMPETING WITH Ca2+ FOR BINDING TO SERCA2a 
 It is generally accepted that PLB decreases the apparent Ca2+ affinity of the 
SERCA2a, while having little or no effect on the Vmax of the enzyme measured at 
saturating Ca2+ concentration (2, 3).  However, whether PLB increases the KCa of 
Ca2+-ATPase activation by decreasing the actual Ca2+ binding affinity of the enzyme 
(21, 23, 44, 51) or by affecting one or more catalytic steps in the reaction cycle (36-
41) has remained unclear.  Cantilina et al. (38) originally proposed that that PLB 
decreases the apparent Ca2+ affinity of SERCA2a by slowing the isomeric transition 
that follows binding of the first Ca2+ ion, enabling cooperative binding of the second 
Ca2+ ion.  According to this model, PLB does not affect the actual Ca2+ binding 
affinity of SERCA2a (the actual amount of Ca2+ bound to the enzyme at a given low 
Ca2+ concentration), but rather the kinetics of enzyme activation by bound Ca2+.  On 
the other hand, our cross-linking results suggest that mutually exclusive binding of 
PLB and Ca2+ is the underlying mechanism of Ca2+-ATPase inhibition by PLB.  If 
PLB competes for Ca2+ binding to SERCA2a by stabilizing the Ca2+-free enzyme in 
E2, and antagonizing formation of E1, then by mass action, PLB should decrease the 
fraction of Ca2+ pumps available to bind and transport Ca2+ at sub-saturating Ca2+ 
concentration.  This would be manifested as a decrease in the apparent Ca2+ affinity 
of the Ca2+-ATPase (2, 3).  
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 a.  USING CROSS-LINKABLE PLB SUPERSHIFTERS TO
 TEST FOR COMPETITIVE BINDING OF PLB AND Ca2+ TO 
 SERCA2a  
 Ideally, to test the theory that PLB competes with Ca2+ for binding to 
SERCA2a, Ca2+ binding assays would be used to directly determine if a population of 
Ca2+ pumps expressed alone and free from PLB bind Ca2+ with higher affinity than a 
population of Ca2+ pumps co-expressed with PLB.  Unfortunately, accurate 
measurement of Ca2+ binding affinity with 45Ca2+ requires relatively high expression 
levels of the Ca2+ ATPase (52), which is difficult to achieve in recombinant systems 
(53).  As an alternative, we have shown that the Ca2+ affinity of the enzyme is 
accurately estimated by assaying Ca2+ inhibition of PLB cross-linking to SERCA2a.  
For example, Fig. 9 shows that PLB cross-linking was inhibited by micromolar 
Ca2+concentration over the same concentration range as enzyme activation occurs. 
However, since cross-linking assays cannot be used to assess the Ca2+ affinity of 
SERCA2a expressed alone, the direct effect of PLB on Ca2+ affinity has yet to be 
determined.  I overcame this limitation by instead comparing the effects of series of 
cross-linkable PLB mutants of increasing inhibitory strength on Ca2+ binding to the 
Ca2+ pump.  If PLB competes for Ca2+ binding to the Ca2+-ATPase, then as PLB 
becomes a stronger inhibitor of enzyme activity, higher concentrations of Ca2+ should 
be required to dissociate it from the Ca2+ pump.  
 Two cross-linkable supershifters, PLB3 (N27A, N30C, L37A-PLB) and PLB4 
(N27A, N30C, L37A, V49G-PLB), were made by combining the N30C cross-linking 
mutation with other gain-of-function mutations (Fig. 15).  PLB3 and PLB4 are 
strongly inhibitory compared to N30C-PLB (which has a normal inhibitory strength 
(21)), while remaining cross-linkable to the Ca2+-pump, thus allowing their physical 
interactions with SERCA2a to be measured simultaneously with their functional 
effects on enzyme activity.  The results, described in detail below, showed that higher 
concentrations of Ca2+ were required to both activate the enzyme co-expressed with 
the increasingly inhibitory PLB mutants and to dissociate the PLB mutants from the 
Ca2+ pump, consistent with PLB competing with Ca2+ for binding to the enzyme.    
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 b.  USING CROSS-LINKABLE PLB SUPERSHIFTERS IN 
 CONJUNCTION WITH D351A-SERCA2a TO TEST FOR 
 COMPETITIVE BINDING OF PLB AND Ca2+ 
 To test directly for competition between PLB and Ca2+ for binding to 
SERCA2a, I also took advantage of the Ca2+-pump mutant, D351A.  During catalysis, 
Asp351 is phosphorylated by ATP to form the high-energy acylphosphoprotein 
intermediate, E1~P·Ca2 (Fig. 4).  Replacement of aspartic acid at this position renders 
the enzyme catalytically inactive (53, 54). Although inactive at the site of ATP 
hydrolysis, D351A retains the ability to bind Ca2+ and maintains the thermodynamic 
 
 
 
 
Figure 15.  Complete Amino Acid Sequences of the Cross-linkable PLB Mutants, N30C-PLB, 
PLB3, and PLB4  I and II designate cytoplasmic and transmembrane domains of PLB, 
respectively.  Domain IA contains Ser16 and Thr17, the residues phosphorylated in response to β-
adrenergic stimulation.  The point mutations N27A in domain IB (28) and L37A (26, 27) and 
V49G (22, 31) in domain II are all supershifting mutations.  The N30C mutation in domain IB 
allows PLB to be cross-linked to Lys328 of SERCA2a with KMUS (21).  For consistency with 
previous publications, N30C-PLB was made on the Cys-less PLB background in which Cys 
residues 36, 41, and 46 were mutated to Ala (6, 21-23). From Akin, B.L., Chen, Z., and Jones, L.R 
(2010) J.Biol.Chem. 285, 28540-28552. 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equilibrium between E1 and E2 (53, 55, 56).  Therefore, if PLB acts by stabilizing E2 
and shifting the E1·Ca2 ↔ E2·PLB equilibrium away from E1, then like the wild-type 
enzyme, higher concentrations of Ca2+ should be required to dissociate the 
increasingly inhibitory PLB mutants from D351A.  The advantage of using D351A 
for these experiments is that enzyme turnover is prevented, therefore the system is at 
equilibrium with respect to Ca2+ binding (Fig. 4).  The results showed that like wild-
type SERCA2a, higher concentrations of Ca2+ were required to inhibit cross-linking 
of the increasingly inhibitory PLB mutants to D351A.    
   
 c.  DETERMINING THE EFFECT OF PLB ON MAXIMAL 
 Ca2+-ATPASE ACTIVITY 
If PLB binding and Ca2+ binding to SERCA2a are mutually exclusive, and 
micromolar Ca2+ concentration completely dissociates PLB from the Ca2+ pump, then 
at saturating Ca2+concentration PLB should have no effect on maximal enzyme 
activity, relative to SERCA2a expressed alone.  On the other hand, in several recent 
studies PLB was reported to either decrease (44) or increase (42, 43, 45) the Vmax of 
the Ca2+-ATPase.  To address this discrepancy directly, maximal Ca2+-ATPase 
activity of SERCA2a expressed alone was compared to that of SERCA2a co-
expressed with PLB mutants of normal (N30C-PLB) and superinhibitory strength 
(PLB3 and PLB4).  Importantly, prior to functional analysis, quantitative Western 
blotting was used to carefully determine protein expression levels in the membranes, 
and Ca2+-ATPase activities were corrected for variability in SERCA2a expression 
between preparations. The results showed that PLB molecules of normal inhibitory 
strength (N30C-PLB) did not significantly affect the Vmax of the Ca2+-ATPase, 
whereas the superinhibitory PLB mutants, PLB3 and PLB4, reduced the Vmax of the 
enzyme substantially. 
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 3.  HYPOTHESIS 3: PLB BINDS EXCLUSIVELY TO THE E2·ATP 
 CONFORMATION OF THE Ca2+ PUMP 
  a.  INVESTIGATING THE CONFORMATIONAL SPECIFICTY 
  OF THE PLB TO SERCA2a BINDING INTERACTION USING 
  THE EFFECTORS TG, VANADATE, AND NUCLEOTIDES  
  (ATP, ADP AND AMP) 
 In previous studies we have shown that PLB cross-linking to SERCA2a is 
completely inhibited by Ca2+ (E1·Ca2), thapsigargin (E2·TG), and Pi (E2·Pi and E2-
P), but augmented substantially by ATP (6, 21-23).  Based upon these results we 
proposed that PLB binds exclusively to the Ca2+-free E2 state of SERCA2a, 
preferentially with bound nucleotide, E2·ATP.  According to this model, the 
superinhibitory PLB mutants, PLB3 and PLB4, should also bind preferentially to the 
E2·ATP state, only more tightly than N30C-PLB.  Therefore, to gain further insights 
on the specific conformation of the Ca2+ pump that binds PLB, and to estimate the 
relative binding affinities of the PLB mutants for SERCA2a, the effects of 
thapsigargin, vanadate, and nucleotides on PLB cross-linking to SERCA2a were 
determined.  The results indicate that the PLB supershifters also act by stabilizing the 
E2·ATP conformation of the Ca2+ pump.  Moreover, we were able to estimate the 
binding affinity of the different PLB mutants for SERCA2a.  In the presence of ATP, 
N30C-PLB had an affinity for E2·ATP approaching that of vanadate (micromolar), 
whereas PLB3 and PLB4 had much higher affinities, several fold greater than even 
TG, the highest affinity SERCA2a inhibitor yet reported (nanomolar or higher). 
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CHAPTER 2—EXPERIMENTAL PROCEDURES 
A.  MATERIALS 
 The cross-linking agent KMUS was purchased from Pierce.  [γ-32P]ATP was 
obtained from PerkinElmer Life Sciences, and thapsigargin and sodium 
orthovanadate were purchased from Sigma.   
 
B.  MUTAGENISIS AND BACULOVIRUS PRODUCTION 
 The baculovirus expression system was used to co-express the canine 
isoforms of both WT and mutant SERCA2a and PLB in insect cell membranes. 
Mutation of canine SERCA2a and PLB cDNAs was conducted as described 
previously (27).  For consistency with previous cross-linking studies, N30C-PLB was 
made on the Cys-less PLB background, in which Cys residues 36, 41, and 46 were 
mutated to Ala (21).  N30C-PLB has been previously well characterized, and is fully 
functional with an inhibitory potency similar to wild-type PLB (21).  In control 
experiments, identical results were obtained when N30C-PLB was made on the wild-
type PLB background with Cys residues 36, 41, and 46 unaltered (data not shown).  
cDNAs encoding PLB3 and PLB4 were generated on the wild-type PLB cDNA 
background inserted in the transfection vector pVL1393, using the QuickChange 
XL-Gold system (Stratagene).  D351A was made similarly using canine cardiac 
SERCA2a cDNA as the template (21).  All mutated cDNAs were confirmed by DNA 
sequencing of the plasmid vectors.  Baculoviruses encoding mutated proteins were 
generated as described previously with BaculoGold (Pharmengen) linearized 
baculovirus DNA (21). 
 
C.  PROTEIN EXPRESSION AND CHARACTERIZATION 
 Sf21 insect cells were co-infected with baculoviruses encoding PLB and 
SERCA2a as described previously (27).  Viral titers were adjusted to give an 
expression level of PLB to SERCA2a of approximately 4:1, as used in previous 
publications (6, 21-23).  Cells were harvested 60 h after co-infection, washed with 
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phosphate-buffered saline, and homogenized with a Polytron for 90 s at 15,000 rpm.  
Crude microsomal pellets were then collected by centrifuging at 48,000 x g for 20 
min.  Microsomes were re-suspended at a protein concentration of 6-10 mg/ml in 0.25 
M sucrose, 10 mM MOPS (pH 7.0) and stored frozen in small aliquots at -40 °C.  
Protein concentrations were determined by the Lowry method.  PLB and SERCA2a 
contents in the membrane samples were determined by quantitative Western blotting 
with the monoclonal antibodies, 2D12 and 2A7-A1, respectively (21).  Only 
membranes expressing PLB and SERCA2a at a molar ratio of approximately 4:1 were 
used for further analyses. 
 
D.  Ca2+-ATPASE ASSAY  
 Ca2+-ATPase activities were measured at 37 °C in buffer containing 50 mM 
MOPS (pH 7.0), 100 mM KCl, 3 mM MgCl2, 3.0 mM ATP, 5 mM NaN3, 3 µg/ml of 
the Ca2+ ionophore, A23187, and 1 mM EGTA.  Ionized Ca2+ concentrations were set 
by varying the CaCl2 concentration from 0-1.2 mM.  In certain assays, only maximal 
Ca2+-ATPase activity was measured in the absence of EGTA and with 50 µM added 
CaCl2 (Figs. 16 and 17).  Some assays were conducted in the presence and absence of 
the anti-PLB monoclonal antibody, 2D12, which reverses PLB inhibition of 
SERCA2a (5, 6, 57).  Ca2+-dependent ATPase activities were determined in a 
reaction volume of 1 ml containing 50 -100 µg of membrane protein during a 30 - 60 
min incubation.  Pi release from ATP was measured colorimetrically (21).  Maximal 
Ca2+-ATPase activities ranged between 15 and 25 µmol of Pi/mg of protein/h for all 
samples, which is approximately 25-40% of the maximal Ca2+-ATPase activity 
typically reported for dog cardiac SR vesicles (57).  In some Ca2+-ATPase assays, 
small aliquots were taken from the assay tubes during the incubations, in order to 
simultaneously measure PLB cross-linking to SERCA2a (see below).  KCa values are 
the Ca2+ concentrations at which the Ca2+-ATPase is half maximally active as 
determined directly from the data plots.  
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E.  CROSS-LINKING PLB TO SERCA2a 
 1.  STANDARD CROSS-LINKING (SMALL SCALE)  
 In most experiments, cross-linking of N30C of PLB to Lys328 of SERCA2a 
with KMUS was conducted identically as previously described (22).  Cross-linking 
reactions were conducted with 11 µg of membrane protein in 12 µl of buffer.  The 
final concentrations of PLB and SERCA2a in the cross-linking tubes were 1.2 µM 
and 0.3 µM, respectively.  Standard cross-linking buffer contained 50 mM MOPS 
(pH 7.0), 3.0 mM MgCl2, 100 mM KCl, 3 mM ATP, and 1 mM EGTA with zero to 
1.2 mM added CaCl2.  In some experiments, ATP concentrations were varied, or 
different nucleotides were used, as indicated in the figure legends.  In the experiments 
with the SERCA2a inhibitors TG and vanadate, TG was added from a 1 mM stock 
solution in ethanol, and sodium orthovanadate was added from a 15 mM stock 
solution in H2O.  Cross-linking reactions were started by adding 0.75 µl of 1.6 mM 
KMUS dissolved in Me2SO (final KMUS concentrations 0.1 mM), and incubated for 
2 min at room temperature.  Reactions were stopped by adding 7.5 µl of gel loading 
buffer containing 15% SDS and 100 mM dithiothreitol.  Samples were subjected to 
SDS-PAGE, and Western blotting with the anti-PLB antibody, 2D12, using 125I-
protein A or alkaline phosphatase for PLB visualization.  In the experiments 
measuring the effects of 2D12, blots were probed directly with 125I-2D12, and protein 
A was omitted (6).  Radioactive signals (representing SERCA2a with bound PLB) 
were quantified using a Bio-Rad Personal Fx Phosphoimager.  The Ki values for 
inhibition of PLB cross-linking were determined directly form the data plots, and is 
the Ca2+, TG, or vanadate concentration at which cross-linking was 50% inhibited. 
  
 2.  LARGE SCALE CROSS-LINKING 
 In order test the catalytic activity of PLB-bound SERCA2a, PLB was cross-
linked to SERCA2a on large-scale (PLB/SER), and then the catalytic activity of 
PLB/SER was determined by measuring its ability to hydrolyze ATP and to be 
phosphorylated with [γ-32P]ATP or 32Pi, to form E1~P and E2-P, respectively.  “Pre-
cross-linking” the membranes on large scale in advance allowed for multiple 
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phosphorylation experiments (by both [γ-32P]ATP and 32Pi) to be performed on 
identical membranes, eliminating a potential source of variability.  Also, pelleting and 
re-suspending the cross-linked membranes prior to storage eliminated the excess 
cross-linker, ATP, and Ca2+ present during the initial cross-linking reaction.   
 Large scale cross-linking was done similar to the standard cross-linking 
described above, only 2.75 mg instead of 11 µg of membranes were used per reaction 
tube, and 300 µl Ca2+-EGTA buffer was added to achieve free Ca2+ concentrations 
between 0 and 16.7 µM. Reactions were started with the addition of 187 µl of 1.6 
mM KMUS in Me2SO and incubated for 3 min; the final reaction volume was 3 ml. 
The reactions were stopped with the addition of 125 µl of 500 mM glycine and 500 
mM DTT.  The cross-linked membranes were centrifuged for 10 min at 100 K at 4 °C 
in a Beckman TL-100 centrifuge. The membranes were re-suspended in 10 mM 
MOPS and 0.25 M sucrose (pH 7.2) and stored in small aliquots at -80 °C.   
    
 3. CROSS-LINKING UNDER Ca2+-ATPASE CONDITIONS 
 To assess Ca2+ effects on PLB cross-linking to SERCA2a, experiments were 
conducted at 37 °C in the same buffer used for measurement of Ca2+-ATPase activity, 
as described above.  15 min after initiation of Ca2+-ATPase reactions with ATP, 80 µl 
aliquots containing 8 µg of membrane protein were taken from Ca2+-ATPase assay 
tubes and cross-linked with 1 mM KMUS for 15 s, giving the maximal cross-linking 
obtainable at each Ca2+ concentration tested.  Reactions were stopped with gel 
loading buffer, and samples were then processed as described above.  Cross-linking 
of PLB to D351A to assess Ca2+ affinity was determined under identical conditions.  
 It should be pointed out that the heterobifunctional cross-linker KMUS reacts 
irreversibly with Lys328 of SERCA2a and N30C of PLB whether the two proteins are 
bound or not.  If the two proteins are bound when the cross-linker is added, then PLB 
is irreversibly cross-linked to SERCA2a by a single KMUS molecule.  If the proteins 
are not bound when the cross-linker is added, then N30C of PLB can react with one 
KMUS molecule, and Lys328 of SERCA2a can react with a second KMUS molecule, 
thus blocking additional cross-linking of the two proteins as new PLB-SERCA2a 
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complexes are formed.  Therefore, the amount of PLB-SERCA2a complex detected 
by cross-linking is essentially a "snapshot" of the amount of PLB-SERCA2a complex 
present at the time at which the cross-linker is added.  
 
F.  MONITORING FORMATION OF THE PHOSPHORYLATED 
INTERMEDIATES, E1~P AND E2-P 
 1.  PHOSPHORYLATION OF E1·Ca2 BY [γ-32P]ATP 
 Phosphorylation of SERCA2a using [γ-32P]ATP was conducted by incubating 
11 µg of membrane protein (virgin membranes or pre-cross-linked membranes) in 12 
µl buffer containing 50 mM MOPS (pH 7.0), 3.0 mM MgCl2, 100 mM KCl, 1 mM 
EGTA, and 0 to 1.2 mM CaCl2.  Maximal E1~P formation was measured in the 
absence of EGTA and with 1 mM added CaCl2. Phosphorylation was initiated by 
adding a final concentration of 200 µM [γ-32P]ATP and conducted for 5 s at room 
temperature.  Reactions were terminated with 7.5 µl of acidic gel loading buffer (pH 
2.4) containing 3% LDS, and LDS-PAGE was conducted under acidic conditions as 
recently described (22). After electrophoresis, proteins were transferred to 
nitrocellulose and the radioactive acylphosphoprotein bands were visualized by 
autoradiography and quantified with the Fx Phosphoimager.  
 
 2.  PHOSPHORYLATION OF E2 BY 32Pi (BACK DOOR 
 PHOSPHORYLATION) 
 Phosphorylation of SERCA2a by 32Pi to form E2~P was done in buffer 
favoring formation of E2 (i.e. at pH 7.0, in the presence Me2SO and in the absence of 
KCl, ATP, and Ca2+). 11 µg of membranes were added to 12 µl buffer containing 40 
mM MOPS, (pH 7.0), 20 mM MgCl2, 20% Me2SO, and 1.0 mM EGTA. Reactions 
are started by adding 1.0 µl of 3 mM Pi containing trace amounts of 32Pi.  After a 10 
min incubation at room temperature, the reactions were stopped with 7.5 µl LDS-
PAGE sample loading buffer containing 3% LDS and the samples were processed as 
described above for the [γ-32P]ATP-labeled samples. 
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CHAPTER 3—RESULTS 
A.  HYPOTHESIS 1: SERCA2a WITH BOUND PLB IS CATALYTICALLY 
INACTIVE 
 1. LARGE SCALE PRE-CROSS-LINKING OF N30C-PLB TO 
 SERCA2a 
 SERCA2a was co-expressed with N30C-PLB in Sf21 insect cells, and the 
membranes were pre-cross-linked (N30C of PLB to Lys328 of SERCA2a) on large 
scale over a Ca2+ concentration range of 0–16.4 µM using the heterobifunctional 
cross-linker KMUS.  After the cross-linking reactions were terminated, the 
membranes were pelleted, re-suspended, and stored in small aliquots at -80 °C until 
needed.  The pre-cross-linked membranes were characterized by Western blotting 
with the anit-SERCA2a (2A7-A1) and anti-PLB (2D12) monoclonal antibodies.  
Total SERCA2a content in the membrane samples is shown in the upper panel of Fig. 
16A, and the fraction of Ca2+ pumps pre-cross-linked to PLB  (PLB/SER) is shown in 
the lower panel.  As predicted based upon previous results, as Ca2+ concentration 
during the pre-cross-linking reaction was increased, N30C-PLB cross-linking to 
SERCA2a was inhibited.  The plot of PLB/SER content in the membranes is shown 
in Fig. 16B.  Maximal Ca2+-ATPase activity of the pre-cross-linked membranes was 
then measured at saturating Ca2+ concentration (50 µM Ca2+).  Percent maximal Ca2+-
ATPase activity was then plotted against PLB/SER for each pre-cross-linked sample 
(Fig. 16B).  Importantly, maximal Ca2+-ATPase activities were inversely proportional 
to PLB/SER levels detected in the membranes by Western blotting.  This indicates 
that there is a tight correlation between PLB cross-linking to SERCA2a, and 
inhibition of Ca2+-dependent hydrolysis of ATP by the Ca2+ pump.  This result 
demonstrates directly that when PLB is irreversibly bound to SERCA2a, the enzyme 
is catalytically inactive, and suggests that PLB immobilizes the enzyme in a Ca2+-free 
state.  Although this result shows that the overall catalytic cycle of SERCA2a is 
blocked by PLB binding, I went on to test whether the phosphorylation half-reactions 
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(forming E1~P and E2-P from [γ-32P]ATP and 32Pi, respectively) were also blocked 
by PLB binding  
  
 2.  PHOSPHORYLATION OF PRE-CROSS-LINKED MEMBRANES 
 WITH [γ-32P]ATP AND 32Pi to from E1~P and E2-P 
 The membrane samples containing N30C-PLB pre-cross-linked to SERCA2a 
over a range of Ca2+ concentrations (0–16.4 µM) were phosphorylated under 
conditions favoring maximal phosphorylation by either  [γ-32P]ATP (at pH 7.0, in 
 
 
 
 
 
 
Figure 16.  Effect of PLB Cross-linking to SERCA2a on Maximal Ca2+-ATPase Activity  N30C-
PLB and SERCA2a were co-expressed in Sf21 insect cells. The membranes were then pre-cross-
linked on large scale with the heterobifunctional cross-linker KMUS over a range of Ca2+ 
concentration 0-16.4 µM, as described in the METHODS.  The pre-cross-linked membranes were  
then pelleted and re-suspended prior to Western blot characterization and functional analysis.  A, 
Pre-cross-linked membrane samples were subjected to SDS-PAGE and immunoblotting with the 
anti-SERCA2a (upper blot, SERCA2a) and anti-PLB (lower blot, PLB/SER) antibodies.  PLB/SER 
shows SERCA2a cross-linked to PLB. B, The plot shows the PLB/SER content in the samples pre-
cross-linked at the Ca2+ concentration shown on the axis (blue).  Percent maximal Ca2+-ATPase 
activity of the same samples measured at 50 µM Ca2+ (red).        
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buffer containing MgCl2, KCl, and high Ca2+ concentration) or 32Pi, (at pH 7.0, in the 
presence Me2SO and in the absence of KCl, ATP, and Ca2+) to from E1~P and E2-P, 
respectively.  Autoradiographs showing formation of E1~P and E2-P are shown in 
Fig. 17A.  N30C-PLB cross-linking to SERCA2a was inhibited as the Ca2+ 
concentration during the pre-cross-linking reaction was increased, and formation of 
both E1~P and E2-P increased as cross-linking was inhibited (Fig. 17A).  The plots of 
the signals of formation of E1~P and E2-P were virtually super-imposable with each 
other and with the plot of maximal Ca2+-ATPase activity.  Therefore, formation of the 
phosphorylated intermediates, E1~P and E2-P, and maximal Ca2+-ATPase activity 
was inversely proportional to PLB/SER content in the membranes (Fig. 17B). This 
inverse correlation between PLB cross-linked to SERCA2a and E1~P and E2-P 
formation corroborates the results of the Ca2+-ATPase assay, further supporting idea 
that SERCA2a with PLB bound is catalytically inactive.  
 
 
 
 
Figure 17.  Effect of PLB Cross-Linking to SERCA2a on Maximal E1~P and E2-P Formation   
A, Autoradiogram shows maximal E1~P and E2-P formation from [γ-32P]ATP and 32Pi , 
respectively, in membranes containing N30C-PLB and SERCA2a pre-cross-linked to SERCA2a at 
the Ca2+ concentration shown. B, Plot shows percent maximal E1~P formation (purple x’s), E2-P 
formation (green triangles), and Ca2+-ATPase activity (red circles) measured in the pre-cross-linked 
membranes, plotted against the percent maximal cross-linking signal PLB/SER (blue squares).   
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 3.  RESOLUTION OF PLB-FREE SERCA2a (CATALYTICALLY 
 ACTIVE SERCA2a) FROM PLB/SER (CATALYTICALLY INACTIVE 
 SERCA2a)  
When cross-linked to PLB, SERCA2a undergoes a small mobility shift that 
causes it to run at a slightly higher molecular weight on acrylamide gels than PLB-
free SERCA2a (6).  I took advantage of this cross-linking induced mobility shift in 
order to resolve SERCA2a from PLB/SER, to definitively determine if PLB/SER is 
phosphorylatable by either [γ-32P]ATP or 32Pi.  Three specific pre-cross-linked 
samples containing ~100%, 50%, and 0% PLB/SER (0%, 50%, and 100% maximal 
Ca2+-ATPase activity, respectively) were phosphorylated with either [γ-32P]ATP or 
32Pi, subjected to LDS-PAGE, and transferred to nitrocellulose.  Autoradiographs of 
the radioactive signals of E1~P and E2-P formation were obtained.  The [γ-32P]ATP 
series was probed with 2A7-A1 (anti-SERCA2a antibody) and the 32Pi series was 
probed with 2D12 (anti-PLB antibody) followed by alkaline phosphatase.  
The cross-linking-induced mobility shift is clearly visible in the Western blot 
detecting the Ca2+-ATPase protein (Fig. 18A, SERCA2a panel 1).  The ~100% cross-
linked sample ran as a single, slightly higher molecular weight band (PLB/SER).  The 
~50% cross-linked sample ran as a doublet with an upper band containing PLB/SER, 
and a slightly lower band containing PLB-free SERCA2a.  In the ~0% cross-linked 
sample, the Ca2+ pump ran as a single lower band (PLB-free SERCA2a).  Consistent 
with this interpretation, in the 2D12 Western blot showing only SERCA2a cross-
linked to PLB (Fig. 18A, PLB/SER panel 2), only the upper band of the SERCA2a 
doublet reacted with the anti-PLB antibody.  These results confirm that PLB/SER and 
PLB-free SERCA2a run with slightly different mobility on acrylamide gels, forming 
two distinct bands.  When the previously obtained autoradiographs showing 
formation of E1~P and E2-P (Fig. 18A, E1~P panel 3, and E2-P panel 4) were 
superimposed over the SERCA2a doublet, only the lower band containing PLB-free 
SERCA2a had been phosphorylated by either [γ-32P]ATP or 32Pi.  Therefore, whereas 
PLB-free SERCA2a readily underwent the kinetic half-reactions to form both E1~P 
and E2-P, PLB/SER remained entirely unphosphorylatable under all conditions.  
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These results confirm the hypothesis that SERCA2a with PLB bound is entirely 
catalytically inactive.   
 
Figure 18.  Phosphorylation of Pre-Cross-Linked Membranes and LDS-PAGE Resolution of 
PLB-free SERCA2a from PLB/SER  N30C-PLB was pre-cross-linked to SERCA2a with KMUS 
at 0, 0.62, and 16.4 µM Ca2+ concentration and pelleted to remove all Ca2+ and excess cross-linker.  
Pre-cross-linked membranes were subjected to LDS-PAGE and Western blotting with the anti-
SERCA2a (2A7-A1) and anti-PLB (2D12) antibodies, followed by alkaline phosphatase for protein 
visualization.  Prior to LDS-PAGE, some of the pre-cross-linked membranes were phosphorylated 
under conditions favoring maximal phosphorylation by [γ-32P]ATP or 32Pi, and autoradiographs 
showing the radioactive signals of E1~P and E2-P formation were obtained.  A, panel 1 shows the 
total SERCA2a content in membrane samples pre-cross-linked at the Ca2+ concentration shown.  
Panel 2 shows only SERCA2a cross-linked to PLB (PLB/SER).  Panel 3 shows the radioactive 
signal of E1~P formation form [γ-32P]ATP. Panel 4 shows the radioactive signal of E2-P formation 
by 32Pi.  Superimposition of panel 3 over panel 1 shows that only the lower band of the SERCA2a 
doublet was phosphorylated by [γ-32P]ATP to form E1~P.  Superimposition of panel 4 over panel 2 
shows that only PLB-free SERCA2a was phosphorylated by 32Pi to form E2-P.  B, Close-up 
showing PLB/SER, total SERCA2a (SERCA2a), and maximal phosphorylation by [γ-32P]ATP 
(E1~P) of the membrane sample pre-cross-linked at 0.62 µM Ca2+ concentration.  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B.  HYPOTHESIS 2: PLB DECREASES THE Ca2+ AFFINITY OF SERCA2a 
BY COMPETING WITH Ca2+ FOR BINDING TO THE ENZYME 
 1.  CO-EXPRESSION OF SERCA2a WITH N30C-PLB, PLB3 AND 
 PLB4 
 Using the Baculovirus expression system, SERCA2a was expressed alone in 
Sf21 insect cells, or co-expressed with N30C-PLB, PLB3, and PLB4.  Protein 
expression levels in the membrane samples were determined by Western blotting with 
the anti-SERCA2a (2A7-A1) and anti-PLB (2D12) monoclonal antibodies.  Fig. 19 
shows that similar levels of SERCA2a and PLB (± 20%) were co-expressed in the 
different membrane preparations.  It should be noted that under the conditions used 
for SDS-PAGE (7% SDS), all three of the PLB mutants were entirely monomeric.     
 
 
Figure 19.  Amido Black Staining and Immunoblot of SERCA2a Co-Expressed with 
N30C-PLB, PLB3, and PLB4.  SERCA2a and N30C-PLB, PLB3, or PLB4 were co-
expressed in Sf21 insect cells. Membrane samples (11 µg) were then subjected to SDS-PAGE, 
transferred to nitrocellulose, and the nitrocellulose sheet stained with Amido Black (left panel).  
The nitrocellulose sheet was then cut in half, and the upper portion was probed with the anti-
SERCA2a antibody, 2A7-A1, and the lower half was probed with the anti-PLB antibody, 
2D12, followed by 125I-protein A (right panel).  Control experiments showed that the 2D12 
antibody bound with equal strength to all three PLB mutants (data not shown). From Akin, 
B.L., Chen, Z., and Jones, L.R (2010) J.Biol.Chem. 285, 28540-28552. 
 
  
  37 
 2.  Ca2+ ACTIVATION OF Ca2+-ATPASE ACTIVITY AND Ca2+ 
 INHIBITION OF PLB CROSS-LINKING TO SERCA2a 
Ca2+-stimulation of Ca2+-ATPase activity of SERCA2a expressed alone and 
SERCA2a co-expressed with N30C-PLB, PLB3, and PLB4 was measured (Fig. 20).  
Based upon Western blots, Ca2+-ATPase activities were corrected for variability in 
expression levels between preparations. SERCA2a expressed alone exhibited typical 
ATP hydrolysis, with half-maximal activation of Ca2+-ATPase activity occurring at 
0.16 µM Ca2+ (KCa = 0.16 µM), and maximal enzyme activity reached at the 
saturating Ca2+ concentration of 1-2 µM (Fig. 4A and Table 1).  At Ca2+ 
concentrations greater than 2 µM, substantial back inhibition of the enzyme by Ca2+ 
was observed (58, 59).  Co-expression of SERCA2a with N30C-PLB increased the 
KCa value for enzyme activation approximately 2-fold, from 0.16 µM to 0.33 µM, 
with little or no effect on the Vmax of the enzyme measured at 1-2 µM Ca2+ (Fig. 20A 
and Table 1).  The effect of N30C-PLB on enzyme activity observed here is identical 
to the effect of wild-type PLB reported previously (27).  In contrast to N30C-PLB, 
PLB3 and PLB4 had large effects on both the KCa of enzyme activation and on Vmax. 
TABLE 1  
KCa values (µM) for Ca2+-ATPase activation and E1~P formation, and Ki values (µM) 
for Ca2+ inhibition of PLB cross-linking  SERCA2a was expressed alone or co-expressed 
with N30C-PLB (N30C), PLB3 or PLB4 in insect cell microsomes. Ca2+-ATPase activities 
and cross-linking were determined under identical conditions in the presence and absence 
of the anti-PLB antibody, 2D12, as described in the text. The *KCa values shown in 
parentheses were calculated based upon the maximal activity determined for SERCA2a 
expressed alone (see Results).  Results are means ± S.E. of 4-6 determinations.    
KCa values Ki values 
Ca2+-ATPase activity E1~P  Cross-linking  
Protein 
Expressed 
- 2D12 + 2D12   - 2D12 + 2D12 
SERCA2a 0.16 ± 0.01 0.16 ± 0.02 0.11 ± 0.02 ND ND 
 + N30C 0.33 ± 0.02 0.19 ± 0.00 0.36 ± 0.04 0.35 ± 0.03 ND 
 (*0.35 ± 0.02)     
 + PLB3 0.53 ± 0.05 0.26 ± 0.02 1.16 ± 0.19 0.88 ± 0.02 0.27 ± 0.01 
 (*0.88 ± 0.03)     
 + PLB4 0.70 ± 0.04 0.36 ± 0.01 2.05 ± 0.25 1.80 ± 0.17 0.45 ± 0.08 
(*1.49 ± 0.02)  
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The KCa values were increased 3.3-fold (0.53 µM Ca2+) and 4.4-fold (0.70 µM 
Ca2+) by PLB3 and PLB4, respectively, when calculated based on the highest Ca2+-
ATPase activity achieved by SERCA2a co-expressed with these two mutants, which 
occurred at 2 µM Ca2+.  It should be noted that at 2 µM Ca2+ concentration, the Vmax 
of the enzyme was inhibited by approximately 30% by both PLB3 and PLB4, relative 
to the same amount of SERCA2a expressed alone or with N30C-PLB (Fig. 20A).  
Nevertheless, complete reversal of Ca2+-ATPase inhibition by PLB3 and PLB4 did 
occur at much higher Ca2+ concentrations (in the range of 100 - 200 µM), Ca2+ 
concentrations at which significant back inhibition of the enzyme occurred.  Thus, in 
Ca2+-ATPase assays, SERCA2a co-expressed with PLB3 or PLB4 can never achieve 
its maximal turnover rate, even though very high Ca2+ concentrations do completely 
reverse Ca2+-ATPase inhibition by the supershifters.  To correct for back inhibition of 
the enzyme by Ca2+, we also calculated the KCa values for SERCA2a co-expressed 
with N30C-PLB, PLB3, and PLB4 using the Vmax value for SERCA2a expressed 
alone (Fig. 20A, grey lines intersecting the abscissa) (*KCa values).  When calculated 
by this method, the *KCa values for SERCA2a co-expressed with N30C-PLB, PLB3, 
and PLB4 were 0.35 µM, 0.88 µM, and 1.49 µM, respectively (Table 1, parentheses).  
These corrected *KCa values indicate that 2.2-fold, 5.5-fold, and 9.3-fold higher Ca2+ 
concentrations are required to half-maximally activate SERCA2a co-expressed with 
N30C-PLB, PLB3, and PLB4, respectively.  
Next, the relative binding affinities of the PLB mutants for SERCA2a were 
estimated by measuring Ca2+ inhibition of PLB cross-linking to the enzyme. All three 
PLB mutants cross-linked only to the cardiac Ca2+ pump expressed in insect cell 
membranes, and all cross-linking results reported here depict the PLB monomer 
bound to SERCA2a (21) (see EXPERIMENTAL PROCEDURES).  In the absence of 
Ca2+, strong cross-linking of all three PLB mutants to Lys328 of SERCA2a was 
observed, and cross-linking was completely eliminated by increasing Ca2+ 
concentration (Fig. 20B).   The Ki values for Ca2+ inhibition of N30C-PLB, PLB3, 
and PLB4 cross-linking to SERCA2a were 0.35, 0.88, and 1.8 µM Ca2+, respectively 
(Table 1).  These Ki values for Ca2+ inhibition of cross-linking agree closely with the 
*KCa values determined for half-maximal activation of Ca2+-ATPase activity.  This 
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Figure 20.  Ca2+ activation of Ca2+-ATPase Activity and Ca2+ Inhibition of Cross-linking   
SERCA2a was expressed alone or co-expressed with N30C-PLB, PLB3, or PLB4 in Sf21 cells and 
SERCA2a and PLB expression levels were determined by Western blotting.  Panel A depicts Ca2+-
ATPase activities measured as described under "EXPERIMENTAL PROCEDURES". Enzyme 
activities were normalized to expression levels of SERCA2a expressed alone.  The grey line 
intersecting the ordinate indicates the 50% Vmax value determined for SERCA2a expressed alone. Panel 
B shows cross-linking of the PLB mutants to SERCA2a determined under identical conditions as the 
Ca2+-ATPase assay. Aliquots were taken from the Ca2+-ATPase assay and cross-linked for 15 sec with 
1mM KMUS at 37°C. Samples were then subjected to SDS-PAGE and immunoblotting with the anti-
PLB antibody, 2D12. Protein bands in the upper panel show SERCA2a cross-linked with the PLB 
monomer. PLB cross-linking is quantified in the graph below.  The graph in Panel C was derived from 
the data in panels A and B. Percent maximal PLB cross-linking to SERCA2a (determined in the 
absence of Ca2+) was calculated at each Ca2+ concentration for each PLB mutant, and then plotted 
against the percent inhibition of Ca2+-ATPase activity by PLB obtained at the same Ca2+ concentration. 
The percent inhibition of Ca2+-ATPase activity by PLB at each Ca2+ concentration was calculated by 
dividing the Ca2+-ATPase activity of membranes expressing SERCA2a plus PLB by the Ca2+-ATPase 
activity of membranes expressing SERCA2a alone, and multiplying by 100. From Akin, B.L., Chen, Z., 
and Jones, L.R (2010) J.Biol.Chem. 285, 28540-28552. 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demonstrates a strong correlation between PLB binding to E2, and decreased Ca2+ 
affinity of SERCA2a determined by the Ca2+-ATPase assay.  This conclusion is 
strengthened by plotting the percent maximal PLB cross-linking to SERCA2a 
(determined at each Ca2+ concentration covering the range from 0.12 µM to 200 µM), 
against the percent inhibition of Ca2+-ATPase activity determined at the same Ca2+ 
concentrations (Fig. 20C).  For all three PLB mutants, regardless of inhibitory 
strength, there was strong correlation (R2 = 0.97) between extent of PLB cross-
linking to SERCA2a and degree of enzyme inhibition.  These data strongly suggest 
that SERCA2a with bound PLB is catalytically inactive, and point to competitive 
binding of PLB and Ca2+ as the mechanism of enzyme inhibition. 
 
 
Figure 21.  PLB Effect on Formation of the Phosphorylated Enzyme Intermediate  Ca2+ 
stimulation of phosphoenzyme formation by [γ-32P]ATP was determined for SERCA2a expressed 
alone, and co-expressed with each PLB mutant. The upper panel is the autoradiograph depicting the 
radioactive phosphoenzyme, and results are plotted below (dark lines).  For comparison, Ca2+ 
effects on N30C-PLB (squares), PLB3 (circles), and PLB4 (triangles) cross-linking to SERC2a are 
also displayed (grey lines), taken from Fig. 20B. From Akin, B.L., Chen, Z., and Jones, L.R (2010) 
J.Biol.Chem. 285, 28540-28552. 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3.  Ca2+ STIMULATION OF E1~P FORMATION CORRELATED 
 WITH Ca2+ INHIBITION OF PLB CROSS-LINKING TO SERCA2a 
Consistent with the Ca2+-ATPase results, when Ca2+ stimulation of 
phosphoenzyme formation from ATP was monitored similar shifts in KCa by the 
different PLB mutants were observed (Fig. 21).  The KCa for SERCA2a expressed 
alone was 0.11 µM, whereas when co-expressed with N30C-PLB, PLB3, and PLB4, 
the KCa values were 0.36 µM, 1.16 µM, and 2.05 µM (Table 1), respectively.  These 
KCa values are nearly identical to the Ki values determined for Ca2+ inhibition of PLB 
cross-linking (grey lines).  These results are particularly significant due to the fact 
that back inhibition of the Ca2+ pump is not a factor when phosphoenzyme formation 
from [γ-32P]ATP is monitored, therefore, no correction for loss of enzyme turnover at 
high Ca2+ concentration is required when KCa values are estimated by this method.   
 
4.  THE EFFECT OF 2D12 ON Ca2+-ATPASE ACTIVITY AND PLB 
 CROSS-LINKING 
The anti-PLB monoclonal antibody, 2D12, recognizes residues 7-13 of PLB 
and reverses PLB inhibition of the Ca2+-pump by physically disrupting PLB binding 
to SERCA2a (6).  2D12 reverses enzyme inhibition by wild-type PLB (38) and 
N30C-PLB virtually completely (6), but only partially reverses the effects of several 
supershifting PLB mutants on Ca2+-ATPase activity (58).  This suggests that the PLB 
supershifters may bind more tightly to the Ca2+ pump than wild-type PLB or N30C-
PLB, but this has not been demonstrated directly.  Therefore, in order to confirm 
tighter binding of the PLB supershifters, and to show that the Ca2+ affinity of the 
enzyme is restored commensurate with dissociation of PLB from SERCA2a, we 
measured the effect of 2D12 on N30C-PLB, PLB3, and PLB4 cross-linking to 
SERCA2a simultaneously with Ca2+-ATPase activity.   
Ca2+-ATPase activity of SERCA2a co-expressed with N30C-PLB, PLB3, and 
PLB4 was measured in the presence of 8 µg of 2D12 (4.44 µM), a concentration 
sufficient to completely saturate PLB (Fig. 22, A-C).  As shown previously (6), the 
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2D12 antibody restored the Ca2+ affinity of SERCA2a co-expressed with N30C-PLB 
nearly completely, decreasing the KCa from 0.33 to 0.19 µM Ca2+, compared to 0.16 
µM Ca2+ for SERCA2a expressed alone (Table 1).  On the other hand, 2D12 only 
partially restored the Ca2+ affinity of the enzyme co-expressed with the 
superinhibitory mutants PLB3 and PLB4, shifting the KCa values from 0.53 to 0.26 
µM for PLB3, and from 0.70 to 0.36 µM for PLB4.  Also, whereas 2D12 had little or 
no effect on the Vmax of the enzyme co-expressed with N30C-PLB, 2D12 increased 
the Vmax of the enzyme co-expressed with PLB3 and PLB4 significantly.  In the 
 
 
 
Figure 22.  Effect of 2D12 on Ca2+-ATPase activity (A-C) and PLB cross-linking to SERCA2a 
(D-F)  Ca2+-ATPase activities were determined in the presence (2D12) and absence (Con) of 2D12 
as described under "EXPERIMENTAL PROCEDURES" for membranes co-expressing SERCA2a 
and each PLB mutant. Grey lines show results obtained for membranes expressing SERCA2a 
alone.  Cross-linking of PLB to SERCA2a was determined under identical conditions as the Ca2+-
ATPase assay. From Akin, B.L., Chen, Z., and Jones, L.R (2010) J.Biol.Chem. 285, 28540-28552. 
.  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presence of the antibody at 1-2 µM Ca2+, Ca2+ pumps co-expressed with PLB3 and 
PLB4 achieved 80 - 95% of the maximal activity of Ca2+ pumps expressed alone.  
 The effects of 2D12 on PLB cross-linking during the same assay are shown in 
Fig. 22, D-F. Consistent with previous results, 2D12 inhibited cross-linking of N30C-
PLB to the Ca2+ pump nearly completely in the absence of Ca2+ and at all Ca2+ 
concentrations tested (6).  This explains why Ca2+ pump inhibition by N30C-PLB is 
30% or less at each Ca2+ concentration tested when Ca2+-ATPase activity was 
measured in the presence of 2D12.  On the other hand, PLB3 and PLB4 cross-linking 
to SERCA2a in the absence of Ca2+ was substantially reduced by addition of 2D12, 
but not eliminated altogether (25% and 53% maximal cross-linking persisted, 
respectively).  Even in the presence of the antibody, Ca2+ concentrations of 1 µM or 
higher were required to completely dissociate PLB3 and PLB4 from the Ca2+ pump 
(E and F).  These cross-linking results agree well with the results of the Ca2+-ATPase 
assays, which showed that the enzyme was significantly inhibited by PLB3 and PLB4 
even in the presence of 2D12.  In experiments not shown, the binding affinity of PLB 
for 2D12 was determined to be 0.1 µM.  Therefore, we conclude that the binding 
affinities of PLB3 and PLB4 for SERCA2a must be very high, at least within the 
range at which PLB binds 2D12.  
 
5.  THE EFFECT OF Ca2+ ON PLB CROSS-LINKING TO D351A 
In order to test directly for competition between PLB and Ca2+ for binding to 
SERCA2a, we took advantage of the Ca2+-pump mutant, D351A.  During catalysis, 
Asp351 is phosphorylated by ATP to form the high-energy acylphosphoprotein 
intermediate, E1~P·Ca2 (Fig. 4).  Replacement of aspartic acid at this position renders 
the enzyme catalytically inactive (53, 54). Although inactive at the site of ATP 
hydrolysis, D351A retains the ability to bind Ca2+ and maintains the thermodynamic 
equilibrium between E1 and E2 (53, 55, 56).  Therefore, if PLB acts by stabilizing E2 
and shifting the E1·Ca2 ↔ E2·PLB equilibrium away from E1, then this effect should 
be fully reproducible with D351A.  The advantage of using D351A for these 
experiments is that enzyme turnover is prevented; hence the system is at equilibrium 
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Figure 23.  Ca2+ effect on PLB cross-linking to D351A  Ca2+ inhibition of N30C-PLB cross-
linking to wild-type SERCA2a (A) and D351A (B) was determined under Ca2+-ATPase assay 
conditions, as described under "EXPERIMENTAL PROCEDURES."  PLB/SER designates the 
PLB monomer cross-linked to the Ca2+ pump at 110 kDa, and free PLB monomers  (PLB1) and 
dimers (PLB2) are visible below at 6 kDa and 12 kDa, respectively.  The full autoradiographs 
are shown, demonstrating the highly specific cross-linking reaction; PLB cross-linked 
exclusively to expressed wild-type SERCA2a or D351A in Sf21 membranes.  C, Graph of Ca2+ 
inhibition of N30C-PLB cross-linking to wild-type SERCA2a and D351A.  D, Ca2+ inhibition of 
N30C-PLB, PLB3, and PLB4 cross-linking to D351A.  Ki values for Ca2+ inhibition of cross-
linking to D351A are listed in RESULTS. From Akin, B.L., Chen, Z., and Jones, L.R (2010) 
J.Biol.Chem. 285, 28540-28552. 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with respect to Ca2+ binding (Fig. 4).  Consistent with previous results with 
SERCA1a, we first confirmed that the D351A mutant made from SERCA2a exhibited 
no Ca2+-ATPase activity, and was not phosphorylatable by [γ-32P]ATP to form E1~P 
(54), nor by Pi to form E2-P (53) (data not shown).   
Next, the affinity of D351A for Ca2+ was compared to that of wild-type 
SERCA2a by measuring Ca2+ inhibition of N30C-PLB cross-linking.  In the absence 
of Ca2+, D351A and wild-type SERCA2a bound comparable amounts of N30C-PLB 
(Fig. 23, A and B).  However, a strikingly lower Ca2+ concentration was sufficient to 
disrupt N30C-PLB cross-linking to D351A (Ki = 18 nM) compared to wild-type 
SERCA2a (Ki = 280 nM) (Fig. 23C).  In fact, the Ca2+ affinity of D351A determined 
by this method (18 nM) is approximately 9-fold higher than the Ca2+ affinity of wild-
type SERCA2a estimated by Ca2+-ATPase assay (0.16 µM in Table 1).  Assuming 
that N30C-PLB decreases the Ca2+ affinity of D351A by approximately 2-fold (as it 
does for wild-type SERCA2a), the Ca2+ affinity of D351A expressed alone is likely 
even higher than this, in the range of 10 nM.  This remarkably high Ca2+ affinity for 
D351A was first reported by MacIntosh et al. (55), but subsequently not confirmed 
(56) (see DISCUSSION).  Fig. 23A also points out the highly specific nature of the 
PLB to SERCA2a cross-linking reaction, with PLB cross-linking exclusively to the 
Ca2+ pump protein expressed in Sf21 membranes.    
Ca2+-inhibition of N30C-PLB, PLB3, and PLB4 cross-linking to D351A was 
then measured (Fig. 23D).  As predicted from results with wild-type SERCA2a, 
progressively higher concentrations of Ca2+ were also required to dissociate N30C-
PLB (Ki = 18 ± 3 nM), PLB3 (Ki = 131 ± 25 nM) and PLB4 (Ki = 234 ± 23 nM) from 
D351A (means ± S.E from 4 determinations).  Fig. 23D demonstrates unambiguously 
that N30C-PLB and the supershifting PLB mutants, PLB3 and PLB4, inhibit Ca2+ 
binding to D351A. This result is consistent with the hypothesis that PLB competes 
with Ca2+ for binding to SERCA2a.  
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 C.  HYPOTHESIS 3: PLB BINDS EXCLUSIVELY TO THE E2·ATP 
CONFORMATION OF THE Ca2+ PUMP 
  1.  THE EFFECT OF TG AND NUCLEOTIDES ON PLB CROSS-
  LINKING TO WILD-TYPE SERCA2a  
 To investigate the specific conformation of the Ca2+ pump that binds PLB, and 
confirm the relative binding affinities of the PLB mutants for SERCA2a, the effects 
of TG and nucleotides on PLB 
cross-linking to SERCA2a 
were measured in the absence 
of Ca2+.  It was shown 
previously that N30C-PLB 
binds preferentially to the E2 
state of SERCA2a stabilized by 
bound nucleotide (21), and that 
TG antagonizes formation of 
this state.  
 When measured in the 
absence of ATP, TG potently 
inhibited the cross-linking of 
all three PLB mutants to 
SERCA2a (Fig. 24, A and B).  
The Ki values for TG inhibition 
of N30C-PLB, PLB3, and 
PLB4 cross-linking to 
SERCA2a were low and 
similar (0.07 µM, 0.07 µM and 0.10 µM, respectively) (Table 2), and within range of 
Ca2+ pumps present within the reaction tubes (~ 0.3 µM).  Thus, TG bound virtually 
stoichiometrically to the Ca2+ pump (34, 35), whether co-expressed with N30C-PLB, 
PLB3, or PLB4.  However, addition of 3 mM ATP to the assay tubes dramatically 
increased the concentration of TG required to inhibit PLB3 and PLB4 cross-linking to 
   
TABLE 2 
KTG values (µM) for TG inhibition of PLB 
cross-linking to the Ca2+-ATPase 
TG inhibition of PLB cross-linking to wild-type 
SERCA2a (SERCA2a) and D351A was 
determined in the presence (+ATP) and absence 
(No Nuc) of 3 mM ATP. Ki values were the TG 
concentration at which PLB cross-linking was 
50% inhibited as read directly from the data 
plots. Results are the means ± S.E. of 4-5 
determinations. 
 
 KTG values Protein 
expressed 
No Nuc + ATP 
 
SERCA2a   
 + N30C 0.07 ± 0.02 0.23 ± 0.05 
+ PLB3 0.07 ± 0.01 4.87 ± 0.53 
+ PLB4 0.10 ± 0.01 7.78 ± 1.0  
D351A   
+ N30C 0.07 ± 0.005 0.17 ± 0.04 
+ PLB3 0.08 ± 0.02 13.3 ± 5.2 
+ PLB4 0.11 ± 0.02 24.3 ± 1.9 
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SERCA2a.  The Ki values (Fig. 24, A and C) increased from 0.07 µM to 4.9 µM for 
PLB3, and from 0.10 µM to 7.8 µM for PLB4, whereas for N30C-PLB, addition of 
ATP only increased Ki value from 0.07 µM to 0.23 µM (Table 2).  That is a 
remarkable 70-fold (PLB3) and 78-fold (PLB4) decrease in TG binding affinity 
induced by ATP when supershifting PLB mutants are present. It should be pointed 
out that the concentration of PLB present in the reaction tubes was approximately 1.0 
µM, which is considerably lower than the concentration of TG required to 
significantly inhibit cross-linking of PLB3 and PLB4 to the Ca2+-ATPase in the 
presence of ATP (Fig. 24C).  Thus the affinity of the two PLB supershifters for 
E2·ATP must be even greater than the affinity of TG for E2·ATP, which is within the 
nanomolar range or lower (34, 35).  The same results with PLB3 or PLB4 were 
obtained whether membranes were pre-incubated with TG for 5 min or 60 min prior 
 
 
Figure 24.  TG effect on PLB cross-linking  A, autoradiographs showing concentration 
dependence of TG inhibition N30C-PLB, PLB3, and PLB4 cross-linking to SERCA2a, measured 
in the absence (-ATP) and presence (+ATP) of 3 mM ATP. B and C, graphs of TG inhibition of 
cross-linking, determined in the absence and presence of 3 mM ATP, respectively. From Akin, 
B.L., Chen, Z., and Jones, L.R (2010) J.Biol.Chem. 285, 28540-28552. 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to initiation of the cross-linking reactions with KMUS, indicating that the 
supershifters prevent formation of a dead-end complex by TG (34) under these 
conditions.   
 Like ATP, ADP also dramatically increased the Ki value for TG inhibition of 
PLB cross-linking to the Ca2+-ATPase, whereas AMP had no significant effect (Fig. 
25A demonstrated with PLB4).  These results confirm previous findings that both 
ATP and ADP, but not AMP, stabilize the E2 state that favors PLB binding (21).  We 
then measured the binding affinity of SERCA2a for ATP determined at different 
 
 
Figure 25.  Nucleotide Effect on PLB4 Cross-Linking to Wild-Type SERCA2a and 
D351A  A, effect of 3 mM AMP, ADP, ATP, and no added nucleotide (Con) on PLB4 cross-
linking to wild-type SERCA2a.  TG concentrations were varied as indicated.  B, ATP 
stimulation of PLB4 cross-linking to wild-type SERCA2a, determined at different TG 
concentrations. ATP concentrations were varied as indicated. C, ATP stimulation of PLB4 
cross-linking to D351A, determined at different TG concentrations. From Akin, B.L., Chen, 
Z., and Jones, L.R (2010) J.Biol.Chem. 285, 28540-28552. 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concentrations of TG (Fig. 25B).  Successively higher concentrations of ATP were 
required to stimulate PLB4 cross-linking to the Ca2+-ATPase when the concentration 
of TG was increased.  In the absence of TG, the affinity of SERCA2a for ATP was 9 
µM; in the presence of 6.4 µM TG, the affinity of the enzyme for ATP was decreased 
10-fold, to approximately 100 µM (Table 3).  These KATP values for SERCA2a 
measured in the absence of Ca2+ agree well with those in previous reports, and 
confirm for SERCA2a, that TG significantly reduces the affinity of the enzyme for 
ATP at the modulatory nucleotide-binding site (60-62).  Collectively, these results 
demonstrate that PLB binds to a single conformation of SERCA2a, E2 with bound 
nucleotide, and this state is distinct from the E2 conformation binding TG (see 
DISCUSSION), all of which is consistent with the hypothesis that PLB binds 
exclusively to the E2·ATP conformation of the Ca2+ pump.  
 
 2.  THE EFFECTS OF TG AND NUCLEOTIDES ON PLB CROSS-
 LINKING TO D351A-SERCA2a 
 Similar nucleotide effects on PLB binding to D351A were noted.  The Ki values 
for TG inhibition of cross-linking of all three PLB mutants to D351A were low and 
similar when assessed in the absence of ATP, but dramatically increased for PLB3 
and PLB4 when ATP 
was included (Table 2).  
TG also substantially 
decreased the ATP 
binding affinity of 
D351 (Fig. 25C and 
Table 3).  Interestingly, 
the affinity of D351A 
for ATP was only about 
2-fold greater than the 
affinity of wild-type 
TABLE 3 
KATP values (µM) for ATP stimulation of PLB4 
cross-linking to the Ca2+-ATPase, determined at 
different TG concentrations  KATP values are the 
ATP concentration at which cross-linking was half-
maximal as determined directly from the plot. Results 
are the means ± S.E. of 3-5 determinations. 
 KATP values  TG (µM) 
SERCA2a D351A 
 
0 9.0 ± 1.5 4.0 ± 0.9 
 0.23 34.0 ± 7.8  15.3 ± 2.7  
2.11 65.0 ± 10.4  24.0 ± 1.5  
6.41 103 ± 12.0 46.0 ± 4.0   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SERCA2a for ATP (Table 3), which is substantially lower than the ATP binding 
affinity of D351A made from SERCA1a (55, 56) (see DISCUSSION).            
 
 3.  THE EFFECTS OF VANADATE ON PLB CROSS-LINKING TO 
 SERCA2a 
 According to results above with TG, the binding affinities of N30C-PLB and 
the supershifters for the E2 state of SERCA2a are much higher than previously 
predicted (51).  Therefore, to confirm these surprising results, we used a second lower 
affinity Ca2+ pump inhibitor, vanadate, to estimate the binding affinities of the PLB 
mutants for SERCA2a.  Vanadate inhibits the Ca2+-ATPase with micromolar affinity, 
and like TG is proposed to bind preferentially to the nucleotide-free, E2 conformation 
 
 
 
Figure 26.  Vanadate Effect on PLB Cross-Linking to SERCA2a  A, autoradiographs showing 
concentration dependence of vanadate inhibition N30C-PLB, PLB3, and PLB4 cross-linking to 
SERCA2a, measured in the absence (-ATP) and presence (+ATP) of 36 µM ATP. B and C, graphs 
of vanadate inhibition of cross-linking, determined in the absence and presence of 36 µM ATP, 
respectively. From Akin, B.L., Chen, Z., and Jones, L.R (2010) J.Biol.Chem. 285, 28540-28552. 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of the Ca2+ pump (63).  Fig. 26 shows that in the absence of Ca2+ and ATP, vanadate 
inhibited cross-linking of all three PLB mutants to SERCA2a.  However, significantly 
higher concentrations of vanadate were required to inhibit PLB3 (Ki = 46 µM) and 
PLB4 (Ki = 380 µM) cross-linking to SERCA2a, relative to N30C-PLB (Ki = 1.6 µM, 
Fig. 26B).  Moreover, maximal cross-linking of PLB3 and PLB4 to SERCA2a could 
only be inhibited by 80% and 60% at 1 mM vanadate, the highest concentration 
tested.  When 36 µM ATP was included in the buffer, the Ki for vanadate inhibition 
of N30C-PLB cross-linking to SERCA2a was increased 125-fold, from 1.6 µM (no 
nucleotide) to 200 µM vanadate (36 µM ATP), and cross-linking of PLB3 and PLB4 
to SERCA2a became nearly completely vanadate resistant  (Fig. 26C).  At 3 mM 
ATP, vanadate failed to inhibit cross-linking of any PLB mutant to the Ca2+-ATPase 
(data not shown). Thus, results with vanadate also show that PLB binds with 
surprisingly high affinity to the E2 state of SERCA2a when nucleotide is present. 
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CHAPTER 4—DISCUSSION 
The purpose of this dissertation research was to investigate the molecular 
mechanism of PLB regulation of Ca2+-ATPase activity.  Three hypotheses were 
tested, each one specifically designed to address a fundamental point in the 
mechanism of PLB action.  Using chemical cross-linking in conjunction with PLB 
mutants of increasing inhibitory function, new insights were gained on the catalytic 
activity of PLB-bound SERCA2a, the effect of PLB on the Ca2+ affinity and Vmax of 
the enzyme, and the specific conformation of SERCA2a required for PLB binding.   
 
A.  HYPOTHESIS 1: SERCA2a WITH PLB BOUND IS CATALYTICALLY 
INACTIVE 
PLB inhibits Ca2+-ATPase activity of SERCA2a by decreasing apparent Ca2+ 
affinity of the enzyme, and PLB effects on Ca2+ affinity are reversed by 
phosphorylation of PLB by PKA or CaMKII, and by micromolar Ca2+ concentration 
(2, 3).  However, whether disinhibition of the Ca2+ pump requires complete 
dissociation of PLB from the SERCA2a has remained unclear.   In a study in which 
fluorescence resonance energy transfer was used to monitor protein-protein 
interactions between PLB and the Ca2+-ATPase, Mueller et al. concluded that the 
affinity of PLB for the Ca2+ pump is so high that under physiological conditions PLB 
essentially never dissociates (36).  The authors suggested Ca2+-induced structural 
changes in SERCA cause significant conformational rearrangements in PLB, but PLB 
remains tightly bound nonetheless (36).  Similarly, using frequency-domain 
fluorescence spectroscopy to monitor interactions between PLB and the Ca2+ pump, 
Li et al. concluded that dissociation of PLB is not requisite for Ca2+ pump activation 
(37).      
In contrast to the findings of Mueller et al. (36) and Li et al. (37), here it was 
shown definitively that SERCA2a with PLB irreversibly bound (PLB/SER) is 
catalytically inactive (Figs. 15-17).  Whereas PLB-free SERCA2a readily underwent 
the kinetic half-reactions to form both E1~P and E2-P, SERCA2a with PLB bound 
was completely devoid of catalytic activity and entirely unphosphorylatable under all 
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conditions (Figs. 16 and 17).  From these results we conclude that when PLB is 
bound, SERCA2a is immobilized in the Ca2+-free E2 state, and in order for the 
catalytic cycle to resume, PLB must first completely dissociate from the enzyme.  
Therefore, by mass action PLB reduces the fraction of Ca2+-pumps available to bind 
and transport Ca2+, which would be manifested as a decrease in the apparent Ca2+ 
affinity of the enzyme, the hallmark of PLB regulation of SERCA2a (2, 3).  
 
B.  HYPOTHESIS 2: PLB DECREASES THE Ca2+ AFFINITY OF SERCA2a 
BY COMPETING WITH Ca2+ FOR BINDING TO THE ENZYME 
 1.  PLB SUPERSHIFTERES REVEAL COMPETITIVE BINDING OF 
 PLB AND Ca2+ TO SERCA2a 
It is generally accepted that PLB decreases the apparent Ca2+ affinity of the 
Ca2+-ATPase, while having little or no effect on the Vmax of the enzyme measured at 
saturating Ca2+ concentration (2, 3).  However, whether PLB increases the KCa of 
Ca2+-ATPase activation by decreasing the actual Ca2+ binding affinity of the enzyme 
(21, 23, 44, 64), or by affecting one or more catalytic steps in the reaction cycle (36-
41) has remained unclear.  Here this question was addressed directly, using cross-
linkable PLB mutants of increasing inhibitory potency (PLB4 > PLB3 > N30C-PLB). 
We showed that successively higher concentrations of Ca2+ were required to both 
activate the enzyme co-expressed with N30C-PLB, PLB3, and PLB4 and to 
dissociate N30C-PLB, PLB3, and PLB4 from the Ca2+ pump (Figs. 20 and 21).  
Moreover, there was a direct correlation between the degree of PLB binding to 
SERCA2a and the extent of PLB inhibition of Ca2+-ATPase activity at all Ca2+ 
concentrations tested with all three PLB mutants (Fig. 20C).  These results strongly 
suggest that PLB competes with Ca2+ for binding to the Ca2+-ATPase, and that 
SERCA2a with PLB bound is catalytically inactive.   
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2.  CONFIRMING COMPETITIVE BINDING OF PLB AND Ca2+ TO 
  SERCA2a USING CATALYTICALLY INACTIVE D351A 
The Ca2+ pump mutant D351A cannot hydrolyze ATP, but retains strong Ca2+ 
binding and maintains the Ca2+-dependent equilibrium between E1 and E2.  Like the 
wild-type enzyme, progressively higher concentrations of Ca2+ were required to 
dissociate the increasingly potent PLB mutants from D351A.  Thus at each Ca2+ 
concentration tested, progressively more E2·PLB was formed by the increasingly 
inhibitory PLB mutants, meaning that less E1 was available for Ca2+ binding (Fig. 
23D).  Therefore, by stabilizing the enzyme in a Ca2+ free state, PLB decreases Ca2+ 
binding to the pump and alters the kinetics of enzyme activation by Ca2+.      
The results shown here with the PLB supershifters and D351A unambiguously 
confirm that PLB decreases Ca2+ binding to SERCA2a, and provide very strong 
evidence for mutually exclusive binding of PLB and Ca2+ to the Ca2+ pump.  In 
contrast to these results, several other groups have recently suggested that PLB 
binding to SERCA2a is unperturbed by Ca2+ binding (36, 37).  These authors contend 
that localized structural changes in PLB, rather than complete dissociation of PLB 
from SERCA2a, account for the Ca2+-induced inhibition of PLB cross-linking 
observed by our group (36, 37).  However, PLB has been cross-linked to SERCA2a at 
numerous points of interaction located within both domains of PLB and two different 
regions of the Ca2+-pump (6, 21-23), and in each case, PLB cross-linking was 
completely inhibited by micromolar Ca2+ concentration.  Most importantly, in the 
work presented here we showed that higher concentrations of Ca2+ were required to 
inhibit cross-linking of the increasingly inhibitory PLB mutants to both D351A and 
wild-type SERCA2a (Figs. 20 and 23).  Nevertheless, we accept the unlikely 
possibility that PLB does bind to the Ca2+ bound enzyme, but that PLB interactions 
with the enzyme in E1 have not been detected by our cross-linking technique.  
However, we can conclude with certainty that if PLB does bind to the Ca2+-bound 
enzyme, then the PLB binding site in E1 is distinct from the inhibitory PLB binding 
site in E2 described by our work, and one in which PLB does not effect Ca2+ pump 
activity.       
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3.  THE EFFECTS OF PLB ON THE Vmax OF SERCA2a 
According to our model PLB competes with Ca2+ for binding to SERCA2a, 
therefore at saturating Ca2+ concentration PLB should be completely dissociated from 
the Ca2+ pump and have no effect on maximal enzyme activity.  Here we showed that 
PLB molecules of normal inhibitory strength (N30C-PLB) do not significantly affect 
the Vmax of the Ca2+-ATPase (Fig. 20).  This result is contrary to conclusions of 
several recent studies in which PLB was reported to either decrease (44) or increase 
(42, 43, 45) the Vmax of the Ca2+-ATPase.  Using our viral constructs and the 2D12 
antibody, Waggoner et al. (44) recently noted a modest reduction (~20%) in the Vmax 
of SERCA2a expressed alone compared to SERCA2a co-expressed with wild-type 
PLB.  This is in disagreement with an earlier study in which no effect on Vmax was 
noted (64).  We believe that the modest reduction in Vmax observed by Waggoner et al. 
(44) is more apparent than real.  Fig. 20A points out that when Ca2+-ATPase activities 
are carefully corrected for Ca2+ pump expression levels, there is little or no inhibition 
of the enzyme at saturating Ca2+ concentrations when SERCA2a is co-expressed with 
PLB mutants of normal inhibitory potency (N30C-PLB).  Moreover, this relief of 
Ca2+-ATPase inhibition at saturating Ca2+ concentration is entirely consistent with the 
complete dissociation of N30C-PLB from SERCA2a observed at 1-2 µM Ca2+ by 
chemical cross-linking (Fig. 20B).  The studies in which wild-type PLB and some 
other PLB mutants were reported to actually increase the Vmax of the Ca2+-ATPase 
were all conducted with the purified rabbit skeletal muscle enzyme co-reconstituted 
with purified PLB from detergent solution (42, 43, 45).  In this case, it is possible that 
enzyme protection by PLB during the reconstitution process may have artifactually 
affected the results, as was recently suggested (45).  Regardless, in multiple studies 
using cellular expression systems, no increase in Vmax by PLB has been noted (2, 3). 
In contrast to N30C-PLB, the superinhibitory PLB mutants PLB3 and PLB4 
did significantly reduce maximal enzyme activity measured at saturating Ca2+ 
concentration (Fig. 20A).  At Ca2+ concentrations greater than 1-2 µM, the Ca2+ pump 
loses significant activity due to back inhibition of the enzyme by Ca2+ (58, 59).  Ca2+ 
concentrations in excess of 100 µM are required to dissociate PLB3 and PLB4 from 
SERCA2a, therefore the Ca2+ pump co-expressed with PLB3 and PLB4 can never 
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achieve as high of a Vmax as the enzyme expressed alone or co-expressed with N30C-
PLB.  The effects of N30C-PLB and the PLB supershifters on maximal enzyme 
activity observed here are entirely consistent with the model of mutually exclusive 
binding of PLB and Ca2+ as the mechanism of PLB regulation of SERCA2a.   
 
4.  THE PHYSIOLOGICAL EFFECTS OF PLB  
The results shown here illustrate how wild-type PLB is perfectly poised to 
regulate cardiac contractile kinetics in intact myocardium, and may help to explain 
the detrimental effects of superinhibitory PLB on cardiac function observed in 
transgenic mouse models (29-31).  Ca2+ concentrations within the cardiomyocyte 
range from nanomolar to 1-2 µM (1), and the affinity of wild-type PLB for SERCA2a 
allows it to associate and dissociate from the enzyme over the same Ca2+ 
concentration range at which contractile force develops.  At low cytosolic Ca2+ 
concentrations at which myofilament contractile force is low, the affinity of PLB for 
the Ca2+-pump is high and enzyme inhibition by PLB is substantial, but still 
reversible by phosphorylation by protein kinase A (2, 3) or by the 2D12 antibody (5).  
At high Ca2+ concentrations yielding peak contractile force, PLB is completely 
dissociated from the Ca2+ pump and the enzyme is maximally active.  However, for 
supershifting PLB mutants the situation is different. By virtue of their very high 
binding affinities for SERCA2a, the supershifters remain significantly bound to the 
Ca2+ pump and continue to inhibit the enzyme at Ca2+ concentrations that are 
normally saturating.  At Ca2+ concentrations high enough to dissociate these potent 
PLB molecules from the Ca2+ pump (10-200 µM Ca2+) (Fig. 20), significant back 
inhibition of the enzyme occurs.  Thus, maximal Ca2+-ATPase activity can never be 
realized when SERCA2a is co-expressed with potent PLB supershifters, even after 
phosphorylation of PLB by protein kinase A or after addition of the 2D12 antibody, 
both of which reduce the affinity of PLB for the Ca2+ pump. Therefore, these results 
provide a mechanism to explain why transgenic mice overexpressing the most potent 
PLB supershifters develop cardiac hypertrophy, heart failure, and premature death 
(29-31).   
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5.  STRUCTURAL CONSIDERATIONS: LONG DISTANCE  
 COMMUNICATION BETWEEN THE Ca2+ BINDING SITES AND 
 THE CATALYTIC SITE 
Using PLB as a reporter molecule, we were able to estimate the Ca2+ and 
nucleotide binding affinities of D351A relative to wild-type SERCA2a, and make 
comparisons with previous determinations made for the skeletal muscle enzyme 
(SERCA1a).  In an earlier study, MacIntosh et al. (55) used TNP-8N3-ATP 
photolabeling to measure the Ca2+ and ATP binding affinities of D351A (rabbit 
skeletal isoform) expressed in COS membranes.  The authors found that relative to 
wild-type Ca2+-ATPase, D351A had an extraordinarily high affinity for both Ca2+ (> 
10-fold increase) and ATP (20 - 100 fold increase) (55).  They postulated that Ala 
substitution at Asp351 significantly increases the ATP affinity of the Ca2+-ATPase by 
relieving electrostatic repulsion between the γ-phosphate of ATP and Asp351 of the 
wild-type enzyme.  Moreover, they proposed that mutationally induced 
conformational changes at the site of ATP binding within the cytoplasmic head group 
were transmitted to the Ca2+ binding sites located at the membrane, substantially 
increasing the Ca2+ affinity of the enzyme.  The very high ATP affinity of D351A, 
but not the high Ca2+ affinity, was confirmed in a subsequent study by Marchand et 
al. (56), also with SERCA1a.  In this later report, ATP- and Ca2+-binding affinities 
were determined for the purified enzyme in detergent solution.  
Here, using PLB cross-linking to estimate Ca2+ affinity, we also noted an 
extremely high Ca2+ affinity for D351A, this time using the cardiac muscle isoform 
(SERCA2a).  Our results indicate that D351A has a Ca2+ affinity at least 10 times 
higher than wild-type SERCA2a (Fig. 7A). This result is consistent with the earlier 
findings of MacIntosh et al. (55), but inconsistent with the results of Marchand et al. 
(56).  It is well known that non-ionic detergents like C12E8 and dodecy-maltoside 
substantially decrease the Ca2+-binding affinity of SERCA pumps (65, 66), which 
may explain the failure of Marchand et al. to detect an increase in Ca2+ affinity for 
D351A (56).  
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Regarding ATP affinity, we determined a Kd value of 9 µM for the wild-type 
enzyme, which is well within the range reported by other investigators for ATP 
binding at the low-affinity modulatory binding site of E2 measured in the absence of 
Ca2+ (60-62).  For D351A, we noted a modest 2.3-fold increase in ATP affinity 
relative to wild-type SERCA2a  (Kd = 4.0 µM), in contrast to the two studies above 
which reported a much higher nucleotide binding affinity for D351A measured under 
similar conditions (55, 56).  However, our results appear to be consistent with the 
recently determined crystal structure of the E2(TG)-AMPPCP complex, representing 
E2 with ATP bound at the modulatory site (20).  According to this structure, ATP fits 
more loosely into the modulatory site (ATP binding site in E2) relative to the catalytic 
site.  When ATP is bound to E2, the γ-phosphate is 9Å away from the 
phosphorylation site, making the electrostatic repulsion between the γ-phosphate and 
the negatively charged Asp351 much less pronounced than what occurs when ATP is 
bound to E1 (20). Thus ATP affinity at the modulatory site may be less affected by 
the D351A mutation because the γ-phosphate of ATP does not interact closely with 
Asp351 when ATP is bound here.  Nevertheless, our results with D351A demonstrate 
that there is long-range communication between the catalytic site and the Ca2+ 
binding sites, and removal of the negative charge at Asp351 strikingly enhances the 
Ca2+ binding affinity at the two Ca2+ binding sites in the membrane.  
 
C.  HYPOTHESIS 3: PLB BINDS EXCLUSIVELY TO THE E2·ATP 
CONFORMATION OF THE Ca2+ PUMP 
 Where in the catalytic cycle of SERCA2a does PLB act to slow or inhibit 
enzyme turnover? Mueller et al. (36) and Li et al. (37) have proposed that PLB acts at 
multiple kinetic steps in the Ca2+-pumpʼs reaction cycle. Alternately, others have 
proposed that PLB acts at a single step, but there is disagreement with respect to 
which step. Tada et al. (39), Antipenko et al. (40) have suggested that PLB slows the 
rate of phosphoenzyme decomposition (E2-P to E2·Pi transition, see Fig. 4).  
Cantilina et al. (38) and Afara et al. (41) proposed that PLB blocks the 
conformational change that accompanies binding of the first Ca2+ ion, facilitating 
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binding of the second.  In contrast, we contend that PLB blocks the transition from E2 
to E1, by stabilizing a single SERCA2a conformational state, E2·ATP.  An earlier 
kinetic study by our group (64) showed that PLB had no effect on either the rate the 
E1·Ca to E1ʼ·Ca transition as proposed by Cantilina et al. (38) and Afara et al. (41), 
nor the rate of E2-P to E2·Pi transition, as proposed by others (39, 40).  Here, it was 
shown directly that PLB decreases Ca2+ binding to E1 by stabilizing the enzyme in 
the Ca2+-free E2 state, thereby decreasing the equilibrium constant for Ca2+ binding.  
Moreover, using the effectors thapsigargin, vanadate, 2D12, and nucleotides (AMP, 
ADP, and ATP) we showed that PLB cross-linking was augmented substantially by 
ADP and ATP (E2·ATP) (Fig. 25), but inhibited by thapsigargin (E2·TG) (Fig. 24), 
vanadate (Fig. 26) and by binding of the 2D12 antibody to PLB (Fig. 21).  These 
results support the hypothesis that PLB binds to the E2·ATP conformation of 
SERCA2a and blocks the transition to E1.   
  
 1.  PLB BINDS TO DEPROTONATED E2·ATP  
 Early studies of the Ca2+-ATPase showed that in the absence of Ca2+, the 
intrinsic tryptophan fluorescence of SERCA was substantially increased by ATP and 
ADP, but was unaffected by AMP (60).  This nucleotide-induced increase in 
fluorescence intensity was completely inhibited by TG, which was subsequently 
shown to reduce the affinity of the Ca2+-ATPase for ATP through uncompetitive 
inhibition (61, 62).  Similarly, PLB cross-linking to SERCA2a occurs in the absence 
of Ca2+, is enhanced by ATP and ADP, but inhibited by TG (6, 21).  Based upon 
these similarities, it was suggested that the physiological state detected by changes in 
fluorescence induced by nucleotide binding to E2 (60-62), is the unique E2·ATP state 
that binds PLB (21).  
 In a recent study by Jensen et al. (20), it was suggested that TG stabilizes the 
fully protonated HnE2 state of the Ca2+ pump, and that ATP binding at the 
modulatory site stimulates deprotonation of E2, initiating the transition to E1.  Here, 
using ATP stimulation of PLB cross-linking to measure ATP binding at different TG 
concentrations, we confirmed the ATP affinities of E2 and E2·TG reported previously 
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(60-62).  Moreover, we showed that ATP dramatically increases the resistance of the 
E2·PLB complex to TG, shifting the Ki values for TG inhibition of cross-linking by 
100-200 fold for the supershifters PLB3 and PLB4  (Table 2).  Thus, the PLB 
supershifters and ATP interact synergistically at E2, stabilizing an E2·ATP·PLB 
ternary complex that is remarkably resistant to TG.  These results suggest that the 
E2·ATP state detected by ATP-induced changes in Trp fluorescence (60-62) and by 
chemical cross-linking of PLB (6, 21), may be the deprotonated E2·ATP state with 
ATP bound at the modulatory site.  Moreover, TG may inhibit formation of this 
specific conformation, not by blocking ATP binding, but by hindering ATP 
stimulated deprotonation of the enzyme.  Consistent with this interpretation, PLB 
does not bind to the Pi (Fig. 12) or vanadate (Fig. 26) bound forms of the enzyme, 
both of which interact with protonated HnE2 state like TG (67).  Also as observed 
with TG, ATP strongly enhances PLB cross-linking to SERCA2a in the presence of 
Pi (Fig. 12) and vanadate  (Fig. 26), being able to compete for Pi (32) or vanadate 
binding (63, 68) to the Ca2+-ATPase.    
  
 2.  THE AFFINITY OF PLB FOR SERCA2a 
 Given TG’s reputation as an extremely potent, irreversible inhibitor of the 
Ca2+-ATPase (34, 35), we were surprised to discover that TG did not disrupt the 
ternary complex between the PLB supershifters and E2·ATP, even when membranes 
were pre-incubated for up to 1 hour with greater than stoichiometric concentrations of 
TG.  Moreover, under these conditions favoring E2·ATP, PLB3 and PLB4 bind even 
more tightly to SERCA2a than does TG, the highest affinity SERCA inhibitor 
identified to date (34, 35).  Crystallographic studies have revealed that TG binds to 
E2 in a cavity formed between transmembrane helices M3, M5, and M7, near the 
cytoplasmic membrane surface (18).  This is on the opposite face of E2 from the PLB 
binding site, which is predicted to extend along the groove formed between 
transmembrane helices M2, M4, and M9, based on cross-linking results  (21, 22, 51).  
Our results suggest that binding of PLB at its site must drastically distort the TG 
binding pocket.  Nonetheless, under enzyme turnover conditions, TG is the more 
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powerful SERCA inhibitor.  In the presence of Ca2+, catalytic activity is completely 
inhibited by TG through formation of a dead-end complex (34), whereas Ca2+-
ATPase inhibition by the PLB supershifters remains reversible, albeit at very high 
Ca2+ concentrations (Fig. 20).  It should be pointed out that TG binding to E1·Ca2+ as 
well as to E2 has been noted in many studies (20, 34, 69-71), and that the ability of 
TG to bind to different conformational states of SERCA may contribute to its 
apparently irreversible effect on Ca2+-ATPase activity.   
 These results with TG indicate that the binding affinity of the PLB 
supershifters (PLB3 and PLB4) for E2·ATP measured in the absence of Ca2+ is in the 
nanomolar range or lower.  The affinities of the PLB mutants for SERCA2a were also 
estimated using the lower affinity Ca2+-pump inhibitor vanadate, and the anti-PLB 
antibody, 2D12.  Vanadate inhibits the Ca2+-ATPase with micromolar affinity, and 
our cross-linking results indicated that N30C-PLB has an affinity for E2·ATP in the 
range of vanadate, whereas the affinities of PLB3 and PLB4 for SERCA2a are much 
greater.  In addition, using 2D12 to estimate the binding affinities of the PLB mutants 
for SERCA2a in the absence of Ca2+, we found that the affinity of PLB for the 2D12 
antibody (0.1 µM) was similar to the affinity of N30C-PLB for Ca2+-ATPase, but less 
than the affinity of the PLB supershifters for SERCA2a.  Therefore, using effectors 
that act both on the Ca2+-ATPase (TG and vanadate) and on PLB itself (2D12), we 
conclude that the affinity of PLB for the Ca2+-pump is much greater than previously 
thought (51).  In the absence of Ca2+ and in the presence of ATP, N30C-PLB has an 
affinity for SERCA2a in the micromolar range, whereas PLB3 and PLB4 bind with 
nanomolar affinity or higher. 
 
D.  CONCLUSION AND FURTURE DIRECTIONS 
 The overall conclusion of this work is that PLB inhibits Ca2+ binding to 
SERCA2a by stabilizing the enzyme in a Ca2+-free E2 state.  Clearly, PLB binding 
has long-range conformational effects on both the cytoplasmic domains and the 
transmembrane domain, and these effects are likely even more profound with the 
PLB supershifters.  ATP binding to E2 accelerates the E2 to E1·Ca2 transition by 
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stimulating H+/Ca2+ cation exchange (20), while at the same time inducing structural 
changes that promote PLB binding.  So, is the conformation of SERCA2a that binds 
to PLB really deprotonated E2·ATP, or Ca2+-free E1 (62), or perhaps something in 
between (70)?  Until the crystal structure of PLB-bound SERCA2a is determined we 
have no way of knowing.  It was recently suggested that TG “rigidifies” the 
transmembrane domain of the Ca2+ pump, making it unresponsive to conformational 
changes occurring within the cytosolic domain (62).  It is this ability of TG to fix the 
transmembrane helices that has enabled the Ca2+-free, TG-bound enzyme to be 
crystallized, providing valuable structural information about the Ca2+-ATPase in 
different E2 states (18). However, all of the E2 structures determined to date have 
been in the presence of irreversible inhibitors like TG or cyclopiazonic acid (72), and 
it is unclear how closely these inhibitor-bound structures resemble other, perhaps 
more physiological states of the enzyme (62).   It is therefore our long-term goal to 
crystallize the Ca2+ pump complexed with PLB in order to provide a structure of E2 
stabilized by a reversible inhibitor that is physiologically active in the heart.  Here, we 
have shown that in the absence of Ca2+, the binding affinities of the supershifters are 
several fold higher than even TG, making the goal of crystallizing the Ca2+-free 
enzyme stabilized by PLB3 or PLB4 seem plausible.    
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